

Hassan Neelam (Orcid ID: 0000-0001-7052-5708)  
Gregson Celia L (Orcid ID: 0000-0001-6414-0529)  
McInerney-Leo Aileen M (Orcid ID: 0000-0002-0059-5732)  
Brandi Maria Luisa (Orcid ID: 0000-0002-8741-0592)  
Duncan Emma L (Orcid ID: 0000-0002-8143-4403)  
Tobias Jon (Orcid ID: 0000-0002-7475-3932)

## Rare and common variants in GALNT3 may affect bone mass independently of phosphate metabolism

### Authors

Neelam Hassan BA BMBCh  
Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School,  
University of Bristol, UK.  
ORCID ID 0000-0001-7052-5708

Celia L Gregson, PhD, FRCP.  
Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School,  
University of Bristol, UK.  
MRC Integrated Epidemiology Unit, Population Health Sciences, Bristol Medical School,  
University of Bristol, UK.  
ORCID ID 0000-0001-6414-0529

Haotian Tang MRes  
MRC Integrated Epidemiology Unit, Population Health Sciences, Bristol Medical School,  
University of Bristol, UK.  
ORCID ID 0000-0002-5717-8390

Marc van der Kamp, MSc, PhD  
School of Biochemistry, University of Bristol, UK.  
ORCID ID 0000-0002-8060-3359

Paul Leo  
Faculty of Health, Translational Genomics Group, Institute of Health and Biomedical  
Innovation, Queensland University of Technology, Australia

Aileen M. McInerney-Leo  
Frazer Institute, The Faculty of Medicine, The University of Queensland, Woolloongabba,  
Australia  
ORCID is 0000-0002-0059-5732

Jie Zheng PhD  
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and  
Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,  
Shanghai, China.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](https://doi.org/10.1002/jbmr.4795). Please cite this article as doi: [10.1002/jbmr.4795](https://doi.org/10.1002/jbmr.4795)

Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

MRC Integrated Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK.

ORCID ID 0000-0002-6623-6839

Maria Luisa Brandi MD, PhD

FIRMO Foundation, Florence, Italy

ORCID ID 0000-0002-8741-0592

Jonathan CY Tang PhD, MSc, BSc, FIBMS

Norwich Medical School, University of East Anglia, Norwich, UK

Clinical Biochemistry, Departments of Laboratory Medicine, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK.

ORCID 0000-0001-6305-6333

William Fraser BSc MBChB MD FRCP FRCPATH EuSpLM

Norwich Medical School, University of East Anglia, Norwich, UK.

Department of Diabetes, Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK

ORCID ID 0000-0003-0556-3358

Michael D Stone BA, MBBS, DM, FRCP

University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, UK.

Elin Grundberg PhD

Genomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO, US

ORCID ID 0000-0001-5415-7896

Anglo-Australasian Genetics Consortium\*

Matthew A. Brown MBBS FRACP MD FAA

Genomics England,  
London, UK.

Emma L Duncan, MBBS FRCP FRACP PhD FAHMS

Dept of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, Faculty of Life Sciences and Medicine, King's College London, UK.

ORCID ID 0000-0002-8143-4403

Jonathan H Tobias, MD PhD FRCP

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School,  
University of Bristol, UK.  
MRC Integrated Epidemiology Unit, Population Health Sciences, Bristol Medical School,  
University of Bristol, UK.

ORCID ID 0000-0002-7475-3932

\*See acknowledgements section for AOGC investigators

Corresponding author:

Jon Tobias, Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical  
School, University of Bristol, Learning and Research building (Level 1), Southmead Hospital,  
Bristol, UK. BS10 5NB. Email: [jon.tobias@bristol.ac.uk](mailto:jon.tobias@bristol.ac.uk)

**Running title (5 words): High Bone Mass *GALNT3* Variants**

## Abstract

Anabolic treatment options for osteoporosis remain limited. One approach to discovering novel anabolic drug targets is to identify genetic causes of extreme high bone mass (HBM). We investigated a pedigree with unexplained HBM within the UK HBM study, a national cohort of probands with HBM and their relatives. Whole exome sequencing (WES) in a family with HBM identified a rare heterozygous missense variant (NM\_004482.4:c.1657C>T, p.Arg553Trp) in *GALNT3*, segregating appropriately. Interrogation of data from the UK HBM study and the Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) revealed an unrelated individual with HBM with another rare heterozygous variant (NM\_004482.4:c.831T>A, p.Asp277Glu) within the same gene. *In silico* protein modelling predicted that p.Arg553Trp would disrupt salt-bridge interactions, causing instability of GALNT3; and that p.Asp277Glu would disrupt manganese binding and consequently GALNT3 catalytic function. Bi-allelic loss-of-function *GALNT3* mutations alter FGF23 metabolism, resulting in hyperphosphatemia and causing familial tumoral calcinosis (FTC). However, bone mineral density (BMD) in FTC cases, when reported, has been either normal or low. Common variants in the *GALNT3* locus show genome-wide significant associations with lumbar, femoral neck, and total body BMD. However, no significant associations with BMD are observed at loci coding for FGF23, its receptor FGFR1, or co-receptor klotho. Mendelian randomization analysis, using expression quantitative trait loci (eQTL) data from primary human osteoblasts and GWAS data from UK Biobank, suggested increased expression of *GALNT3* reduces total body, lumbar spine and femoral neck BMD but has no effect on phosphate concentrations. In conclusion, rare heterozygous loss-of-function variants in *GALNT3* may cause HBM without altering phosphate concentration. These findings suggest that GALNT3 may affect BMD through pathways other than FGF23 regulation, identification of which may yield novel anabolic drug targets for osteoporosis.

**Key words (5): HIGH BONE MASS; EXOME SEQUENCING; MONOGENIC; GALNT3; PHOSPHATE**

## Introduction

Osteoporotic fractures affect 1 in 3 women and 1 in 5 men over the age of 50 worldwide, causing substantial morbidity and mortality, with annual healthcare costs in the USA alone of over \$20 billion(1). Osteoporotic fractures are the leading cause of hospitalisation in women over the age of 45 in the UK, occupying more bed-days than any other condition including breast cancer, diabetes or cardiovascular disease(2). Antiresorptive drugs, such as bisphosphonates or denosumab, currently form the mainstay of osteoporosis treatment. Long-term antiresorptive use is limited by concern regarding rare side effects, including atypical femoral fractures and osteonecrosis of the jaw. In contrast, anabolic treatments actively stimulate new bone formation. Until recently, parathyroid hormone (PTH) derivatives and analogues such as teriparatide (PTH<sup>1-34</sup>) and abaloparatide (PTH-related protein analogue) were the only anabolic treatment options available but the requirement for daily subcutaneous injections and, in many countries, restrictions on prescribing limit their use(3). Romosozumab, was recently approved as an anabolic treatment in the USA and Europe, with once-monthly subcutaneous administration, stimulating bone formation whilst also reducing bone resorption(4). Despite clinical efficacy, concerns regarding cardiovascular side-effects restricted approval by the European Medicines Agency to selected women with severe osteoporosis. Thus, there remains a need for safe, and preferably orally-administered, anabolic treatments for osteoporosis.

Romosozumab is an excellent example of where data from human genetic studies can identify novel drug targets. This agent, which consists of an anti-sclerostin antibody, was developed after the discovery that mutations in and around *SOST*(5,6), the gene encoding sclerostin, underlie the rare diseases sclerosteosis (5) and van Buchem's disease (7); common variants at this locus are also associated with bone mineral density (BMD) (reported in multiple genome-wide association studies (GWAS)) (8). Thus, a highly successful approach to anabolic drug discovery is to identify genetic causes underlying skeletal dysplasias associated with high bone mass (HBM), specifically HBM resulting from excessive osteoblastic bone formation. Both sclerosteosis and van Buchem's disease are associated with pathological features arising from bone overgrowth, such as nerve compression(9). In contrast, several other monogenic disorders have been identified where HBM due to excessive osteoblast activity is an incidental finding, caused by mutations in other Wnt signalling proteins - namely LRP5 and LRP6, usually without sinister consequences of bony overgrowth(10).

The UK HBM study was established to identify new monogenic causes for HBM(11). Pathological variants in known HBM genes (*SOST/LRP5*) were identified in a small minority, leaving most with unexplained HBM(12). Although enrichment of common variant 'high BMD' alleles in known BMD-

associated loci was evident(13), it is likely that further monogenic causes exist which are yet to be discovered. To examine this question, we undertook whole exome sequencing (WES) of our HBM population and analysed the data using a bespoke pipeline developed to identify underlying monogenic variants in individuals and/or families with phenotypes of interest(14). Using this approach, we recently identified a rare missense pathogenic variant in *SMAD9*, segregating with HBM in an autosomal dominant pattern within a UK HBM pedigree(15). The same variant was identified in another two unrelated individuals with HBM sequenced as part of the Anglo-Australian Osteoporosis Genetics Consortium (AOGC)(16). Moreover, common variants at the same locus are associated with BMD in the general population(15). These findings led to the identification of the SMAD-dependent BMP signalling pathway as a potential anabolic target for osteoporosis treatment.

Both *SOST* and *SMAD9* gene discoveries highlight the value of investigating rare monogenic HBM in identifying novel anabolic drug targets. We sought to identify additional novel monogenic causes of HBM by analysing WES data from further kindreds in our UK HBM study.

## Methods

### The UK HBM Study

The HBM study is a UK-based multicentre observational study of adults with unexplained HBM, identified incidentally on routine clinical DXA scanning. Briefly, DXA databases containing 335,115 DXA scans across 13 UK centres were searched; all scans explained by artefact or known causes of high BMD were excluded, principally degenerative disease/osteoarthritis. Unexplained HBM was defined as 1) first lumbar vertebra (L1) Z-score of  $\geq +3.2$  plus total hip (TH) Z-score of  $\geq +1.2$  and/or 2) TH Z-score  $\geq +3.2$  plus L1 Z-score of  $\geq +1.2$ . Full details of DXA database screening and participant recruitment have previously been reported together with the clinical, biochemical and imaging assessments performed(11,15). Baseline recruitment took place between 2005 and 2010 and a follow-up study was performed between 2016 and 2018(17). 337 individuals with unexplained HBM were recruited (240 probands and 97 affected relatives).

### Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) HBM and LBM cases

The AOGC extreme truncate population comprises 1128 Australian, 74 New Zealand, and 753 British unrelated women of white Caucasian ancestry, aged 55 to 85 years,  $\geq 5$  years postmenopausal, with either HBM (TH BMD Z-scores  $+1.5$  to  $+4.0$ ,  $n=1055$ ) or low bone mass (LBM) (Z-scores  $-4.0$  to  $-1.5$ ,  $n=900$ ), with no known secondary cause for in either group(16).

### Whole exome sequencing and analysis

HBM study probands (excluding individuals with pathogenic variants in known HBM genes) underwent whole exome sequencing. Following review of each HBM pedigree, family members were also selected who were related to the index case, and had a phenotype and DNA collected. Where the pedigree spanned three generations, the most distant relatives were sequenced. Additionally, WES was performed in 126 HBM and 493 LBM individuals from AOGC, as well as 240 from the HBM study. Library creation, sequencing, base calling, sequence alignment and variant calling were performed as previously described(18). After quality-filtering, data were analysed for carriage of at least one rare (either novel or population-based minor allele frequency [MAF]  $<0.005$ ) using gnomAD v2.1.1 (Genome Aggregation Database)(19), coding, nonsynonymous single nucleotide variant (SNV) or indel, in a highly conserved region (Genomic Evolutionary Rate Profiling (GERP) score  $>1.5$ ). Data were then filtered based on functional prediction of SNVs using Polyphen-2(20) (Polymorphism Phenotyping v2), SIFT 4G (Sorting Intolerant from Tolerant)(21), PMut(22) and Mutation Taster(23).

HBM pedigrees were analysed for variants segregating appropriately for autosomal dominant inheritance (*i.e.*, carried by affected individuals, not carried by unaffected individuals); compound heterozygous (*i.e.* two different mutation within the same gene) and homozygous inheritance were also considered. Replication was sought by scrutinising similarly filtered data from all UK HBM and AOGC extreme HBM individuals (seeking carriage of the same variant, or other variant within the same gene). For this analysis, a threshold TH or lumbar spine (LS) Z-score  $\geq +2.5$  was used to select the most extreme high BMD individuals from both cohorts. Data from 493 AOGC LBM individuals (with threshold LS Z-score of  $<-0.5$  and TH Z-score  $<-1.5$ ) were similarly scrutinised, as negative controls. Variants of interest were validated using Sanger sequencing.

### Measurement of intact and C-terminal FGF23 concentrations

Human intact (iFGF23) and C-Terminal (cFGF23) forms of FGF23 were analysed by the Immutopics 2nd Generation Enzyme-Linked Immunosorbent Assay (ELISA) kits (Immutopics, Inc. San Clemente, CA, USA). The iFGF23 assay employs a murine monoclonal antibody and an affinity purified goat polyclonal antibody to detect epitopes within the amino terminal and carboxyl-terminal portions of FGF-23, whereas the antibodies in the cFGF23 assay bind to both the intact molecule and large carboxyl terminal fragments of human FGF-23. Each sample was analysed in duplicate as per manufacturer instruction, with interassay coefficient variation (CV%)  $<10\%$  across the assay range of 1.5 - 2200 pg/mL for iFGF23, and 1.5 - 1400 RU/mL for cFGF23.

### Protein structural modelling

Using the crystal structure of *T. guttata* GalNAc-T3 in complex with uridine diphosphate (UDP), manganese, and FGF23 (PDB ID: 6S22)(24) as the template (80% identity to human GalNAc-T3), a homology model was built with SWISS-MODEL (25). Point mutations were introduced and visualized *in silico* using PyMOL v2.4 ([www.pymol.org/2/](http://www.pymol.org/2/)). This highly homologous structure, solved at  $<2$  Å resolution with well-resolved binding of the  $Mn^{2+}$  cofactor and the UDP and FGF23 substrates, allows for confident prediction of the functionally relevant structure of human GalNAc-T3, for which no crystal structure is available

### Literature review and mapping of all reported *GALNT3* mutations

PubMed® ([www.pubmed.ncbi.nlm.nih.gov](http://www.pubmed.ncbi.nlm.nih.gov)) was searched using the terms 'GALNT3', 'GalNAc-T3', 'familial tumoral calcinosis', 'FTC', 'hyperostosis-hyperphosphataemia syndrome' and 'hyperostosis-hyperphosphatemia syndrome'. Abstracts were reviewed to identify case reports of individuals with



*GALNT3* variants. Clinical details (including BMD) were reviewed; identified *GALNT3* variants were collated.

### Identification of common *GALNT3* variants associated with BMD

GWAS assessing LS and femoral neck (FN) (UK10K BMD(26) and GEFOS LS- FN- BMD(27)), total body (TB) (Life-course total body BMD GWAS(27)), and forearm BMD (UK10K BMD) and BMD estimated from heel ultrasound (eBMD) (UK Biobank eBMD(28,29)) were interrogated for associations within  $\pm$  50kb of the coding sequence of *GALNT3*, *FGF23*, *FGFR1* and *klotho*, using the Musculoskeletal Knowledge Portal (MSKKP <https://msk.hugeamp.org>), a data mining platform that includes genomic data relating to 291 musculoskeletal traits from 269 datasets(30). A publicly available GWAS of serum phosphate concentration, conducted in UK Biobank (<http://www.nealelab.is/uk-biobank/>), was also interrogated for associations with the same four loci.

A PheWAS was conducted using the Musculoskeletal Knowledge Portal (MSKKP) (<https://msk.hugeamp.org/>) and GWASATLAS (<https://atlas.ctglab.nl>), of which the latter is an online database of publicly available summary results statistics from 4,756 GWAS from 473 unique studies across 3,302 unique traits and 28 domains(31). Significance for pleiotropic associations used the traditional genome-wide significance threshold for SNP-trait PheWAS ( $p < 5 \times 10^{-8}$ ).

### Mendelian randomization (MR) using osteoblast eQTL data

We performed a two-sample MR. The exposure (*GALNT3*-expression quantitative trait loci [eQTLs]), was identified by searching eQTL data from primary human osteoblasts(32) to identify SNP(s) within 0.5kb of *GALNT3* associated with *GALNT3* expression levels (*cis*-eQTLs). Other phosphate-handling genes (*FGF23*, *FGFR1*, and *klotho*) were similarly evaluated. F statistics were calculated to evaluate instrument strength. The outcome comprised BMD as assessed in the GWAS datasets described above(26,29,33). We also examined possible associations of these eQTLs with serum phosphate concentration, based on the UK Biobank Phosphate GWAS (<http://www.nealelab.is/uk-biobank/>). MR analyses were based on Wald ratios(34) where a single eQTL SNP was identified, or inverse variance weighted (IVW)(35) and generalised IVW(36) where multiple SNPs were available.

## Results

### A HBM pedigree with a segregating *GALNT3* c.1657C>T p.Arg553Trp variant

A pedigree with unexplained HBM, segregating in an autosomal dominant pattern, was identified within the UK HBM population (Figure 1A). Clinical and biochemical characteristics of each individual are summarized in Table 1, with further details below. All recruited individuals from this pedigree had high BMD Z-scores and high BMI. Osteoarthritis and dental overcrowding was common, with all individuals having multiple tooth extractions. There was no history of headaches, nerve compression, or low-trauma fractures. No individuals had received antiresorptive or anabolic drugs. Neither parent had a history of fracture.

#### Clinical features

##### *II.2: Proband*

The proband was a 64-year-old female with BMD Z-scores of +5.2 at first lumbar vertebra (L<sub>1</sub>) and +5.1 at TH. She had no difficulties swimming. She did not have any joint or limb pain and had never fractured. She had required wisdom tooth extractions; and was noted to have minimal unilateral hearing loss on a recent hearing test (type of hearing loss not known). She had hypertension (diagnosed aged 34 years) and hypercholesterolaemia (diagnosed aged 64 years). She received menopausal hormone therapy between ages 50 to 57 years; and had a hysterectomy and bilateral salpingo-oophorectomy for stage 1 uterine cancer at age 62 years.

On examination, her height was 1.62m and weight 89kg (body mass index (BMI) 33.9kg/m<sup>2</sup>). She had mandibular enlargement but no mandibular or maxillary tori; and no cranial nerve impingement. She had signs of osteoarthritis (OA) (palpable crepitus in both knees, and Heberden's nodes bilaterally) but normal range of movement throughout all joints including her spine. Radiographs demonstrated degenerative changes in the hands (carpometacarpal joints and several distal interphalangeal joints), knees (medial and lateral compartments) and lumbar spine (joint space narrowing and osteophytosis).

##### *II.1: Brother of proband*

The proband's 67-year-old brother had BMD Z scores +3.4 at L<sub>1</sub> and +1.8 at TH. He had no difficulties swimming and denied any joint or limb pain. He had fractured his fingers playing cricket aged 16 years and his thumb playing hockey aged 22 years. He had four teeth removed due to overcrowding. He reported gradual bilateral hearing loss (type not known) over the preceding 10 years. He had hypercholesterolaemia; and had undergone a prostatectomy for prostate cancer aged 61 years.

On examination, his height was 1.78m and weight 86kg (BMI 27.1kg/m<sup>2</sup>). He had a small torus arising from the lower left mandible, and lower jaw dental overcrowding. He had Heberden's nodes affecting multiple fingers. He had reduced forward flexion in his lumbar spine but otherwise normal range of joint movement. Radiographs revealed joint space narrowing and osteophytosis affecting multiple distal interphalangeal joints.

### *II.3: Sister of proband*

The proband's 59-year-old sister resided outside of the UK so history was obtained over the telephone, physical examination was not performed, and DXA scanning was performed in her home country.

The sister had BMD Z-scores of +3.3 at L<sub>1</sub> and +2.4 at TH. She had no swimming difficulties. She had no joint or limb pain and had never fractured. Tooth extractions were performed due to dental overcrowding, and she required an orthodontic brace for 3 years. She had hypertension (diagnosed aged 52 years). She was taking regular calcium/vitamin D supplements. Her height was 1.6m and weight 74kg (BMI 28.9kg/m<sup>2</sup>).

### *II.4: Brother of proband*

The proband's 58-year-old brother had BMD Z scores of +2.9 at L<sub>1</sub> and +2.0 at TH. He had no swimming difficulties. He had had bilateral ankle pain for over 30 years (i.e., since approximately age 25 years). He had bilateral hip pain and had bilateral hip replacement for osteoarthritis during the study follow up period. Baseline radiographs revealed severe joint space loss at both hips. He had never fractured. He had wisdom teeth removed aged 27 years. He had hypertension (diagnosed aged 50 years), asthma and depression.

His height was 1.82m and weight 94kg (BMI 28.4kg/m<sup>2</sup>). He had a broad frame. He had no tori and no cranial nerve impingement. He had bilateral knee crepitus.

### Sequencing results

A heterozygous missense variant in *GALNT3* (NM\_004482:exon 4:c.1657C>T, p.Arg553Trp) was identified, present in all affected siblings (Figure 1). The variant (rs764878326) is rare (GnomAD MAF 0.000016 in European non-Finnish populations), with GERP score 4.47, and predicted to be pathogenic by multiple protein-prediction algorithms (probably damaging by PolyPhen, damaging by SIFT, and disease-causing by PMut [pathology score 0.81] and Mutation Taster). No other rare pathogenic variants with appropriate segregation were identified. Sanger sequencing confirmed the variant in each sequenced individual (Figure 1B).

### **A further HBM case with a rare heterozygous *GALNT3* variant**

Scrutiny of other UK HBM cases, and the HBM AOGC arm, identified an unrelated individual with a different rare heterozygous variant in *GALNT3* (c.831T>A, p.Asp277Glu).

### Clinical features

#### *S1: Proband*

This 61-year-old female had a BMD Z-score of +5.2 at L<sub>1</sub> and +3.2 at TH. She was able to swim but had difficulty floating. She had never fractured. She had osteoarthritis and fibromyalgia, and reported widespread pain in her joints and back with muscle spasms. She reported multiple teeth 'breaking' when younger and she required multiple fillings throughout her 20s and 30s. She had a total hysterectomy aged 40 years and a cholecystectomy aged 60 years.

On examination, her height was 1.62m and weight 69kg (BMI 26.3kg/m<sup>2</sup>). She had no tori. Cranial nerve examination was normal. She had osteoarthritic changes in her hands and knees. She had reduced range of movement in her cervical spine but range of movement was normal elsewhere. Radiographs revealed degenerative changes within the hands (joint space narrowing, osteophytosis and subchondral cysts) and knees (joint space narrowing and osteophytosis).

Her mother had a fragility fracture of her hip. Other family information was limited.

### Sequencing results

A rare, heterozygous missense variant in *GALNT3* (NM\_004482.4:c.831T>A, p.Asp277Glu) was identified in the proband. This variant (rs139397826) is rare (MAF 0.000025), with GERP score 2.59, and is predicted pathogenic by multiple protein-prediction algorithms (probably damaging by PolyPhen, damaging by SIFT, and disease-causing by PMut [pathology score 0.92] and Mutation Taster).

### LBM controls

#### *GALNT3 variants in the LBM cohort*

Neither variant (c.1657C>T p.Arg553Trp or c.831T>A p.Asp.277Glu) was observed on interrogation of the AOGC LBM cohort. No other rare pathogenic *GALNT3* variants were identified in this cohort when the same filtering parameters were used.

### Protein structural modelling predicts that p.Arg553Trp and p.Asp277Glu disrupt GALNT3 function

*GALNT3* encodes the 633 amino acid Golgi-associated glycosyltransferase, Polypeptide N-Acetylgalactosaminyltransferase-3 (*GALNT3*). *GALNT3* belongs to a large family of Golgi-associated glycosyltransferases (GalNAc-Ts) that initiate mucin-type O-glycosylation, catalysing the transfer of N-acetyl-D-galactosamine (GalNAc) from uridine-diphosphate-GalNAc (UDP-GalNAc) to a serine or threonine residue on protein substrates, with relatively broad acceptor substrate specificity(24). *GALNT3* consists of a short N-terminal cytoplasmic tail, a hydrophobic transmembrane domain, a central catalytic (glycosyltransferase) domain and a C-terminal ricin B-type lectin (carbohydrate binding) domain with a  $\beta$ -trefoil fold. There are two conserved domains within the glycosyltransferase region: the N-terminal domain (domain A, also known as the GT1 motif) and the C-terminal domain (domain B, also known as the Gal/GalNAc-T motif). The ricin B-type lectin domain binds to GalNAc and contributes to glycopeptide specificity.

The c.1657C>T p.Arg553Trp variant in the first pedigree is located within the carbohydrate-binding lectin domain. Substitution of arginine with tryptophan is predicted to disrupt salt-bridge interactions, leading to instability of the protein (Figure 2).

The c.831T>A p.Asp277Glu variant is located within domain A of the glycosyltransferase domain and is part of the D277XH279 motif involved in Mn<sup>2+</sup> (manganese) coordination. Mn<sup>2+</sup> is key for binding the UDP pyrophosphate group; substitution of aspartate with glutamate is predicted to disrupt Mn<sup>2+</sup> coordination and consequently UDP binding and thus the catalytic function of *GALNT3* (Figure 2).

### ***GALNT3* variants and bone mass**

#### *Rare variants*

Review of the gnomAD database indicates that the loss-of-function (LoF) oe (ratio of observed to expected number of LoF variants) in *GALNT3* is 0.58 (90% CI 0.4 – 0.86) i.e. only 58% of the expected LoF variants are observed. This suggests that *GALNT3* is likely to be under a degree of selection against LoF variants.

Biallelic LoF *GALNT3* variants are known to be associated with the extremely rare autosomal recessive conditions of hyperphosphatemic familial tumoral calcinosis (FTC) and hyperostosis-hyperphosphatemia syndrome (HHS) (OMIM: 211900). Mice homozygous for a LoF *Galnt3* mutation (Trp589Arg), a model for FTC and HHS, have higher areal BMD compared to wild-type mice whilst heterozygous mice had intermediate BMD (16). Mice homozygous for the mutation also had high cortical bone volume and trabecular number on micro CT (37).

Literature review identified 38 novel/rare LoF *GALNT3* variants in humans, all reported in association with FTC and/or HHS (41 homozygotes, 21 compound heterozygotes) (Table 2). DXA-measured BMD Z-scores (at TH and/or LS) were reported in only four individuals with *GALNT3*-associated FTC and HHS (all aged <25 years). Three individuals had normal BMD and one had ‘extremely reduced’ BMD(38). One case series of seven individuals with *GALNT3*-associated FTC and/or HHS reported that Z- and T-scores were ‘within two standard deviations of the mean’ for all individuals apart from one individual who had low T-scores in the context of chronic untreated systemic inflammation(39). *GALNT3* variants associated with FTC/HHS showed no obvious clustering within the structure of the *GALNT3* protein or relative to the two variants described in our HBM individuals (Figure 3).

We sought to clarify the effect of heterozygous or homozygous *GALNT3* rare LoF variants on bone mass by assessing BMD in a family in whom two individuals with FTC were homozygous for a *GALNT3* variant affecting a splice site (c.1524+1G>A) (Figure 4). This variant has previously been shown to result in disruption of the intron 7 donor splice site consensus sequence(40). Both homozygous individuals had normal BMD at both LS and TH; in contrast both carrier parents and their heterozygous sister had Z-scores <-1.0 at LS but normal BMD at TH (Figure 4).

#### *Common variants*

Common variants at the *GALNT3* locus are associated with BMD, as reported in an earlier GWAS in the AOGC cohort (lead SNP rs1863196 with suggestive association with BMD at TH ( $p=2.3 \times 10^{-5}$ ) and LS ( $p=0.037$ ))(16).

Interrogation of subsequent BMD GWAS using MSKPP confirmed the previous suggestive results from AOGC. Significant ( $p < 5 \times 10^{-8}$ ) associations were observed between SNPs in the *GALNT3* locus (chr2:166,554,098 - 166,701,169) and BMD at total body (lead SNP rs7586085,  $p=8.64 \times 10^{-21}$ )(33), femoral neck (lead SNP rs10170839,  $p=1.2 \times 10^{-14}$ )(26), and LS (lead SNP rs11680288,  $p=3.12 \times 10^{-9}$ ) (Table 3); no significant association was found with forearm BMD(26), or eBMD(29) (locus zoom plots for each result: Supplemental Materials Figures S1-S5). Phenome screening revealed an additional genome-wide significant association with type 2 diabetes (lead SNP rs11686403,  $p=9.68 \times 10^{-11}$ ) although not of genome-wide significance when adjusted for BMI (lead SNP rs6710518,  $p=2.86 \times 10^{-5}$ ) (no significant pleiotropic associations were found using GWASATLAS).

Given the effect of *GALNT3* on phosphate metabolism via FGF23 (discussed below), we examined whether common variants in genes coding for other members of the FGF23 pathway (*FGF23*, its receptor *FGFR1*, and co-receptor *klotho*) were also associated with BMD. No associations reached genome-wide significance (Supplemental Table S1).

## **GALNT3 variants and phosphate homeostasis**

### *Rare variants*

Biallelic loss-of-function variants in *GALNT3* cause disorders of phosphate homeostasis, specifically hyperphosphatemic FTC and HHS (41), acting through the FGF23 pathway (42,43). Although heterozygous carriers of FTC/HHS-associated *GALNT3* variants do not show any clinical features of FTC or HHS(44) subtle biochemical abnormalities including slightly elevated phosphate concentrations have been reported (45,46).

Thus in our HBM cases with heterozygous *GALNT3* variants we measured phosphate (II.2, II.4, S1), intact FGF23 (iFGF23) (II.1, II.2, II.4) and C-terminal FGF23 (cFGF23) (II.1, II.2, II.4) concentrations where possible. These results were all in the normal reference range (Table 1).

### *Common variants*

Interrogating the UK Biobank GWAS of phosphate concentrations identified strong associations with variants in the *FGF23* locus (lead SNP rs2970818  $p=3.23 \times 10^{-230}$ ) and *klotho* locus (lead SNP rs7324259,  $p=2.99 \times 10^{-10}$ ). However, associations with loci containing *GALNT3* and *FGFR1* did not reach genome-wide significance (Table 3, Supplemental Table S1).

## **Mendelian randomization studies suggest that *GALNT3* expression reduces BMD**

We used MR to examine whether *GALNT3*, *FGF23*, *FGFR1* or *klotho* expression affect BMD. A single *cis*-SNP, rs13427694, was associated with *GALNT3* mRNA levels in primary human osteoblasts at  $p<0.05$ , providing a weak genetic instrument as reflected by an F statistic of 7.8 (Supplemental Table 2). Three *cis*-SNPs were associated with *FGFR1* mRNA (F statistic 7.0). One *cis*-SNP was associated with *klotho* mRNA, which provided an insufficiently strong instrument for further analysis (F statistic 5.0), whereas no *cis*-SNP was identified for *FGF23*.

As shown in Figure 5, subsequent MR analysis suggested that the *GALNT3* osteoblast eQTL was inversely related to femoral neck (FN), lumbar spine (LS) and total body (TB) BMD, with no associations seen within forearm BMD or heel eBMD, or with serum phosphate levels. While the *FGFR1* eQTL was unrelated to FN, LS or TB BMD, generalized IVW analysis suggested a decrease in forearm BMD, though IVW estimates crossed the null. Notably, osteoblast *FGFR1* expression was related to an increase in phosphate, particularly in generalized IVW analyses.



## Discussion

We report two rare heterozygous missense *GALNT3* variants underlying HBM in two independent kindreds. *In silico* protein modelling predicts that these two variants are likely to result in loss of *GALNT3* function, whether through structural instability (c.1657C>T p.Arg553Trp) which may lead to misfolding and more rapid degradation of the protein, or impairment of manganese binding and consequently loss of catalytic function (c.831T>A p.Asp277Glu).

Analysis of common genetic variants from GWAS supports the suggestion from our HBM studies that *GALNT3* plays an important role in regulating bone mass, given loci within this gene show associations at genome-wide significance with LS, FN and TB BMD. Though genetic associations do not demonstrate a causal role for a given locus, our MR analysis using *cis*-eQTL data from primary human osteoblasts suggests that *GALNT3* expression is causally associated with BMD. The eQTL analysis showed that increased expression of *GALNT3* is associated with reduced BMD, consistent with our finding of two likely LoF *GALNT3* variants causing an increase in BMD.

Our study demonstrates that the association between *GALNT3* and BMD is supported by both rare and common variants and is consistent with findings from mouse models. As shown previously, drug targets with support from monogenic and population genetic studies are more likely to proceed successfully through the drug development pipeline and be approved(47,48). It is possible that targeting *GALNT3*-dependent BMD pathways may open a new avenue in the search for new anabolic treatments for osteoporosis.

It is important to consider potential unwanted effects of targeting *GALNT3*. Three of the four HBM individuals from the index pedigree had osteoarthritis (OA); artefactual increases in BMD due to osteoarthritis were excluded by use of L1 BMD measurements and careful inspection of DXA images. This predisposition to OA is consistent with previous findings from the UK HBM study where individuals with generalised HBM have been shown to be at increased risk of developing OA and requiring joint replacement(17,49). 'Bone forming' features of osteoarthritis have previously been reported in association with HBM(50), perhaps reflecting an underlying tendency to increased osteoblast activity and excess bone formation, thereby contributing to the osteophytosis observed in several individuals. Dental overcrowding also appeared to be common but a torus was only seen in one individual. Individuals with these two rare heterozygous *GALNT3* variants appear to display an otherwise benign clinical phenotype, with an absence of the nerve compression seen with other skeletal dysplasias(5,51).



It is known that biallelic loss-of-function *GALNT3* mutations cause the rare autosomal recessive disorder FTC and HHS in which deficient *GALNT3*-mediated O-glycosylation results in enhanced cleavage and inactivation of the phosphaturic hormone, FGF23, leading to increased/normal inactive C terminal FG23, low intact FGF23 and hyperphosphatemia(43). However whether these rare variants alter BMD has not been assessed in most cases. Two cases of FTC caused by novel variants in *GALNT3* were reported to have very low BMD(38,39). However, both individuals had other clinical risk factors which could lead to low bone mass. The first individual had hypogonadism and reduced physical activity due to extra-skeletal masses(38), whilst the second individual had untreated chronic systemic inflammation(39). It remains unclear if these FTC-associated *GALNT3* variants had any role in directly causing this low BMD alongside disturbing phosphate metabolism.

Acknowledging that we were only able to assess these parameters in a few individuals, the normal phosphate, iFGF23 and cFGF23 concentrations in our heterozygous HBM *GALNT3* cases, raises the possibility that *GALNT3* is able to alter BMD independent of the FGF23 pathway. Interrogation of the UK Biobank phosphate GWAS and our MR analysis further supports this hypothesis. In contrast to total body, lumbar and spinal BMD, our *GALNT3* eQTL was unrelated to circulating phosphate, and though there was a suggestive association between the *GALNT3* genomic region and phosphate, this failed to reach genome-wide significance.

In contrast to *GALNT3*, no SNPs within the *FGF23* genomic region were associated with any BMD parameter at genome-wide significance. The same applies to *FGFR1* and *klotho*, the downstream receptor and co-receptor for FGF23 respectively, defects in which are associated with phosphate abnormalities, likely due to loss of FGF23 activity. This further supports the separation of this pathway from effects on BMD. As expected, *FGF23* and *klotho* were strongly associated with phosphate on GWAS although the association for *FGFR1* did not reach genome-wide significance in the UK Biobank dataset. *FGFR1* cis-eQTLs identified in osteoblast cultures were unrelated to LS, FN and total body BMD. That said, *FGFR1* expression was associated with reduced forearm BMD in generalised IVW analyses, though no effect was seen in IVW analyses, possibly as the latter incorporated fewer SNPs. Whereas *FGFR1* expression had a smaller effect on BMD compared to *GALNT3* expression, unlike the latter, *FGFR1* expression had a strong effect on serum phosphate levels, providing further evidence of dissociation of *GALNT3* and FGF23 function.

Taken together, studies of common genetic variants and gene expression suggest important functional differences between *GALNT3* and FGF23/*FGFR1*/*klotho*, with common variants in the former predominantly affecting BMD, and the latter phosphate homeostasis. Previous studies of *GALNT3* glycosylation activity have focused on FGF23 as its substrate. Given effects of *GALNT3* on BMD appear

independent of phosphate homeostasis, these could be mediated by glycosylation of distinct protein(s) primarily involved in regulating bone mass, which are yet to be identified. HBM caused by heterozygous p.Arg553Trp and p.Asp277Glu *GALNT3* variants, may result from disruption of interactions between GALNT3 and these bone regulatory protein(s).

Bone turnover markers (CTX, osteocalcin and P1NP) in our HBM individuals were either low or towards the lower limit of normal, indicating that bone turnover overall may be suppressed. This is in keeping with previous findings from the UK HBM cohort, where bone turnover markers generally tended to be lower than those in controls (52). This has also previously been found to be the case with some individuals with *LRP5* mutations(53), although others report normal or high turnover(54-56). One possible explanation for this is that generalised HBM may be caused by mechanisms which increase osteoblast activity and bone formation when the HBM phenotype is being developed (i.e. during puberty) and these same mechanisms then suppress bone turnover during later life to maintain the increased BMD(52). Another possible explanation is that these HBM variants lead to wnt activation (similar to HBM variants in *LRP5* and *SOST*) causing suppression of bone resorption as a consequence of the known inhibitory action of wnts on osteoclastogenesis. This mechanism underlies the suppression of bone turnover markers that is seen following use of romosozumab (which leads to wnt pathway activation) (4).

The mechanism by which GALNT3 affects BMD without disturbing phosphate homeostasis requires further investigation to avoid precipitating features of FTC or HHS, particularly as there did not appear to be any obvious clustering or segregation of HBM-associated GALNT3 variants compared to FTC/HHS-associated GALNT3 variants within the structure of the protein. Furthermore, male mice with W589R induced FTC also had infertility, a feature which has not been widely reported in humans with FTC or HHS. GALNT3 is highly expressed in the testis; one case report describes a boy with testicular microlithiasis associated with oligozoospermia(44). The finding that common variants in *GALNT3* on GWAS appear to be protective against type 2 diabetes also raises the concern that inactivating GALNT3 may increase the risk of developing this condition.

There are several limitations to our study. Since phenotyping was only performed in a limited number of family members, information about co-morbidities was not consistently available in the kindreds used for this study. Phosphate and FGF23 measurements were found to be normal but were only tested at one timepoint in some of the HBM cases. Serum phosphate concentration is regulated by several hormones, including parathyroid hormone, as well as being heavily influenced by food intake, neither of which were quantified or measured. It has previously been shown that dietary phosphate intake can influence the development of ectopic calcification in FTC mouse models. High dietary intake

of phosphate in humans has also been associated with larger FTC lesions. Dietary phosphate intake in studied individuals was not documented so it is unclear whether this had any effect on the biochemical phenotype observed in these HBM cases. A further limitation is that the eQTL data used in our study were derived from human osteoblasts obtained from a small sample of 95 donors, hence the derived genetic instruments were relatively weak, risking weak instrument bias.

In conclusion, we report two rare heterozygous *GALNT3* variants as putative causes of HBM. Our study indicates that c.1657C>T p.Arg553Trp and c.831T>A p.Asp277Glu variants are likely to cause loss-of-function of GALNT3. We hypothesise that these *GALNT3* variants may affect BMD through mechanisms which are independent of phosphate and FGF23 regulation. This is supported by evidence from population genetic studies where common variants in *GALNT3*, including a GALNT3 cis-eQTL, are associated with BMD more strongly than with phosphate levels. Further investigation of the mechanism by which this occurs may yield novel anabolic drug targets for osteoporosis treatment.

## Acknowledgements

AOGC investigators comprise: Eugene McCloskey<sup>1</sup>, Geoffrey C Nicholson<sup>2</sup>, Richard Eastell<sup>1</sup>, Richard L Prince<sup>3</sup>, John A Eisman<sup>4,5</sup>, Graeme Jones<sup>6</sup>, Philip Sambrook<sup>7</sup> (deceased), Ian R Reid<sup>8</sup>, Elaine M Dennison<sup>9</sup> and John Wark<sup>2</sup>. NH was supported by the Medical Research Council (MR/V00199X/1), Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (8064/Hassan/WT ISSF 3). CLG was funded by the Wellcome Trust (080280/Z/06/Z), the EU 7th Framework Programme ref 247642 (GEOCODE), a British Geriatric Society travel grant, and Versus Arthritis (formerly Arthritis Research UK) (grant ref 20000). MAB was funded by a National Health and Medical Research Council (Australia) Principal Research Fellowship. ELD was funded by a National Health and Medical Research Council (Australia) Career Development Award (569807). AML is funded by a National Health and Medical Research Council Early Career Fellowship (APP1158111). The AOGC was funded by the National Health and Medical Research Council (Australia) (grant reference 511132). Funding was also received from the Australian Cancer Research Foundation and Rebecca Cooper Foundation (Australia).

<sup>1</sup>University of Sheffield, UK, <sup>2</sup>University of Melbourne, Geelong, Australia, <sup>3</sup>University of Western Australia, Perth, Australia, <sup>4</sup>St Vincent's Clinical School, University of New South Wales, <sup>5</sup>Menzies Research Institute, University of Tasmania, Hobart, Australia, <sup>6</sup>Kolling Institute, Royal North Shore Hospital, University of Sydney, Australia, <sup>7</sup>University of Auckland, New Zealand, <sup>8</sup>Medical Research Council Resource Centre, Southampton, UK

## Contributions of authors

Conceptualization – NH, CLG, ELD, JT

Funding acquisition – NH, CLG, ELD, JT

Data curation – NH, CLG, PL, ELD, MAB

Investigation – NH, CLG, MvDK, HT, MLB, WF, EG, MS, ELD

Methodology – NH, CLG, MvDK, JZ, PL, AML, WF, MAB, ELD, JT

Analysis – NH, MvDK, HT, WF, ELD, PL, AML, CLG

Supervision – CLG, ELD, JT

Writing original draft – NH, JT

Writing – review & editing – NH, MvDK, WF, MLB, CLG, ELD, JT

## Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Disclosures

The authors have no potential conflicts of interest.

## Tables

**Table 1: Clinical and biochemical characteristics of HBM individuals with *GALNT3* c.1657C>T, p.R553W mutations and a further unrelated HBM individual with a *GALNT3* c.831t>A, p.D277E mutation.**

	HBM pedigree <i>GALNT3</i> c.1657C>T, p.Arg553Trp				Additional isolated HBM case <i>GALNT3</i> c.831T>A, p.Asp277Glu
	II.1 Brother	II.2 Proband	II.3 Sister	II.4 Brother	S1
Age	67	64	59	58	61
Sex	Male	Female	Female	Male	Female
Ethnicity	British (white)	British (white)	British (white)	British (white)	British (white)
Height (cm)	178	162	160	182	162
Weight (kg)	86	89	74	94	69
BMI (kg/m <sup>2</sup> )	27.1	33.9	28.9	28.4	26.3
DXA L <sub>1</sub> Z-score	+3.4	+5.2	+3.3	+2.9	+5.2
DXA TH Z-score	+1.8	+5.1	+2.4	+2.0	+3.2
Adult fracture	Yes (only digits)	No	No	No	No
Dental overcrowding	Yes	Yes	Yes	Yes	No
Torus	Yes	No	No	No	No
Nerve compression	No	No	No	No	No
Difficulties with swimming	Not known	No	No	No	Yes
<b>Blood tests <sup>a</sup></b>					
Adjusted calcium (mmol/L)	-	2.43	-	2.28	-
Phosphate (mmol/L)	-	1.2	-	0.9	1.3
iFGF23 (pg/mL)	43.4	52.5	-	22.8	-
cFGF23 (RU/mL)	25.2	59.5	-	28.0	-
ALP (IU/L)	50	78	-	70	65
P1NP (µg/L)	28	27	-	16	15
CTX (µg/L)	0.05	0.09	-	0.09	0.09
Osteocalcin (µg/L)	12.2	12.0	-	12.0	6.0

<sup>a</sup> **Reference ranges:** adjusted calcium 2.25-2.70; phosphate 0.8-1.5; iFGF23 28-121; cFGF23 <100; ALP 20-120; P1NP: postmenopausal female 26–110, male 20–76; CTX 0.1–0.5; osteocalcin 6.8–32.2

**Abbreviations:** BMI: Body Mass index ; DXA: Dual energy X-ray Absorptiometry, iFGF23 – intact fibroblast growth factor-23; cFGF23 – C-terminal fragment fibroblast growth factor-23; ALP: alkaline phosphatase; P1NP: Procollagen type 1 N propeptide; CTX: C-terminal telopeptide of type I collagen

**Table 2: Summary of published case reports of *GALNT3* variants**

Variant	Protein consequence	Clinical consequence	BMD Z-scores	Reference
c.2T>A	Loss of start codon	HHS	NR	Gok et al.(57)
c.41_58 del	p.Arg14Serfs*8	FTC	NR	Garringer et al. (58)
c.254_255delCT	p.Pro85Argfs*6	FTC	2 females, homozygote, skeletal site not specified. Z-scores of +0.7 (age 10) and 0.0 (age 9)	Kisla et al.(59)
c.260-266delGGCAAA	p Arg87Thrfs*19	FTC	2 females (compound heterozygote, age 6 and 8) –Z-scores reported as ‘within 2 SD of mean’	Ramnitz et al.
c.484C>T	p.Arg162*	FTC	NR	Topaz et al.(40), Ichikawa et al. (46), Demellawy et al.(60), Carmichael et al. (61,62)
c.485G>A	p.Arg162Gln	FTC	NR	Ichikawa et al.(63)
c.516-2A>T	p.Cys173Leu fs176*	FTC	2 females (compound heterozygote, age 6 and 8) –Z-scores reported as ‘within 2 SD of mean’(39)	Laleye et al.(64), Ichikawa et al.(46) Ramnitz et al. (39)
c.516-2A>G	p.Cys173 fs176*	FTC/HHS	1 female (age 16) LS -5.1	Masi et al.(38)
c.539G>A	p.Arg180His	FTC	NR	Sun et al. (65)
c.659T>A	p.Ile220Asn	FTC	NR	Sun et al. (65)
c.677delC	p.Ala226Valfs*3	FTC/HHS	NR	Ichikawa al. (63), Dauchez et al.(66)
c.746_749delTCAG	p.Val249Aspfs*8	FTC	One report of 1 female (compound heterozygote, age 6) with Z-scores reported as ‘within 2 SD of mean’	Ramnitz et al. (39) Guerra et al.(67)
c.767G>T	p.Gly256Val	FTC/HHS	NR	Rafaelson et al.(68)
c.782G>A	p.Arg261Gln	FTC	NR	Mahjoubi et al. (69)
c.803-804insC	p.Thr269Asn fs281*	HHS	NR	Ichikawa et al.(70)
c.815C>A	p.Thr272Lys	FTC	NR	Ichikawa et al.(71)
c.839G>A	p.Cys280Tyr	HHS	NR	Gok et al. (57)
c.842A>G	p.Glu281Gly	FTC/HHS	NR	Joseph et al.(45)
c.892delT*	p.Tyr298Thrfs*5	FTC	One report of 1 female (compound heterozygote, age 6) with Z-scores reported as ‘within 2 SD of mean’	Ramnitz et al. (39)
c.966T>G	p.Tyr322*	FTC	NR	Barbieri et al.(72)



c.1076C>A	p.Thr359Lys	FTC	NR	Ichikawa et al. (71)
c.1097T>G	p.Leu366Arg	FTC/HHS	NR	Joseph et al.(45)
c.1102_1103 insT	p.Ser368Phefs*8	FTC	NR	Garringer et al.(58)
c.1245T>A	p.His415Gln	FTC	NR	Yancovitch et al.(73)
c.1312C>T	p.Arg438Cys	FTC/HHS	1 female (compound heterozygote, age 22) (74) TH +1.9 LS +0.3 Forearm +1.0  One report of 1 female (age 36) with T and Z-scores reported as 'within 2 SD of mean' (39)	Yancovitch et al.(73) Dumitrescu et al.(74) Ramnitz et al. (39)
c.1313G>A	p.Arg438His	HHS	NR	Olauson et al.(75)
c.1319C>A	p.Ala440Glu	FTC	NR	Finer at al.(62)
c.1387A>T	p.Arg463*	FTC	NR	Campagnoli et al. (44)
c.1392+1G>A	Splicing error	HHS	NR	Ichikawa at al. (63)
c.1441C>T	p.Gln481*	FTC	NR	Barbieri et al.(72)
c.1460G>A	p.Trp487*	FTC	NR	Garringer et al. (58)
c.1524+1G>A – skip exon 7	Deletion of 44 amino acids from codons 464-508	FTC/HHS	NR	Topaz et al.(40) Frishberg et al.(76), Frishberg et al (42).
c.1524+5G>A – skip exon 7	Deletion of 44 amino acids from codons 464-508	FTC	One report of 1 female (compound heterozygote, age 36) with T and Z-scores reported as 'within 2 SD of mean' (39)	Topaz et al.(40) Ramnitz et al(39)
c.1584_1585insA	p.Pro529Thrfs*17	FTC	1 male (homozygote, age 29) No Z-scores but T-score reported as AP spine -3.9 TH -3.2. Male sibling (homozygote, age 19 with same variant) reported as having T and Z-scores 'within 2 SD of mean'	Ramnitz et al. (39)

c.1626+1G>A – skip exon 8	Deletion of 34 amino acids from codons 509-542	HHS	NR	Ichikawa et al. (70)
c.1681T>A	p.Cys561Ser	FTC	NR	Dayal et al. (77)
c.1720T>G	p.Cys574Gly	FTC/HHS	NR	Ichikawa et al. (63)
c.1774C>T	p.Gln592X	FTC	1 female (compound heterozygote, age 22) (74) TH +1.9 LS +0.3 Forearm +1.0  1 female (compound heterozygote, age 36) with T and Z-scores reported as 'within 2 SD of mean'(39)	Specktor et al. (78) Dumitrescu et al. (74) Ramnitz et al.(39)

Reported as per the sequence variant nomenclature guidelines from the Human Genome Variation Society <http://varnomen.hgvs.org/>

**Abbreviations:** BMD: Bone mineral density; FTC: Familial tumoral calcinosis; HHS: Hyperostosis-hyperphosphatemia syndrome; NR : Not reported; TH: Total hip; LS: Lumbar spine; SD: standard deviation

**Table 3: Genome-wide significant associations of SNPs in the *GALNT3* genomic region ( $p < 5 \times 10^{-8}$ ) in order of significance. Lead SNPs for estimated BMD from heel ultrasound (eBMD), forearm BMD and phosphate are also shown although these did not reach genome-wide significance.**

Trait	Lead SNP	MAF	p value	$\beta$	95% CI low	95% CI high	Odds ratio
Total body BMD(33)	rs7586085	0.41	$8.64 \times 10^{-21}$	-0.0532	-0.064	-0.042	
Femoral neck BMD(26)	rs10170839	0.42	$1.2 \times 10^{-14}$	-0.0594	-0.074	-0.045	
Type 2 diabetes(79-98)	rs11686403	0.41	$9.68 \times 10^{-11}$	-0.022	-0.028	-0.017	0.098
Lumbar spine BMD(26)	rs11680288	0.42	$3.12 \times 10^{-9}$	-0.0542	-0.072	-0.037	
Phosphate	rs777356	0.48	$2.73 \times 10^{-5}$	-0.01019	-0.015	-0.0054	
eBMD(29)	rs12692777	0.40	$7.20 \times 10^{-4}$	-0.0117	-0.018	-0.005	
Forearm BMD(26)	rs34100816	0.27	$1.78 \times 10^{-3}$	-0.0527	-0.085	-0.02	

**Abbreviations:** SNP: single nucleotide polymorphism; MAF: minor allele frequency;  $\beta$ : beta value; CI: confidence interval; BMD: bone mineral density; eBMD: bone mineral density estimated from heel ultrasound; LDL: low density lipoprotein


## Figures

Figure 1

A

I

II



B

II.1

II.2

II.3

II.4




Figure 2




Figure 3




Figure 4







Figure 5





## Figure legends

Figure 1. A: HBM pedigree B: electropherograms with *GALNT3* c.1657C>T variant

Figure 2. A: Overview of *GALNT3* protein structure with R553 indicated with yellow carbons, with salt-bridge hydrogen-bond interactions shown as blue dotted lines. R553W will result in disruption of these salt-bridge interactions, causing instability. B: D277 (Asp277) is shown with yellow carbons and  $Mn^{2+}$  in purple, with the other residues coordinating to  $Mn^{2+}$  (H279 & H415). The D277E mutation is predicted to affect  $Mn^{2+}$  coordination/binding. The UDP substrate, the binding of which will depend on  $Mn^{2+}$ , is shown with cyan carbons and FGF23c with white carbons. Images generated using PyMOL v2.4.

Figure 3: Schematic representation of *GALNT3* protein structure. Arrows at sites of known FTC (in black) and HHS (in blue). Mutations in cases with features of both FTC and HHS are represented in green. HBM mutations are shown in red.

Figure 4: BMD measurements in an Italian pedigree with FTC and *GALNT3* c.1524+1G>A variant

Figure 5: Association of *GALNT3* and *FGFR1* eQTLs with BMD and phosphate

## Supplemental materials

### Tables

**Table S1: Top genome-wide associations for SNPs in the genomic regions of *FGF23*, *FGFR1* and *KL* with BMD parameters and phosphate.**

Abbreviations: SNP: single nucleotide polymorphism; MAF: minor allele frequency;  $\beta$ : beta coefficient; CI: confidence interval; *FGF23*: fibroblast growth factor-23, *FGFR1*: fibroblast growth factor receptor 1; *KL*: klotho; BMD: bone mineral density; FN: femoral neck; LS: lumbar spine; eBMD: estimated BMD from heel ultrasound

**Table S2: *GALNT3* and *FGFR1* osteoblast-derived eQTLs used as genetic instruments for the exposure in two-sample MR. The F-statistic for each genetic instrument is shown together with the method of MR analysis used.**

Abbreviations: eQTL: expressive quantitative trait loci; MR: Mendelian randomization; SNP: single nucleotide polymorphism;  $\beta$ : beta coefficient; *FGFR1*: fibroblast growth factor receptor 1; GIVW: generalised inverse variance weighted; IVW: inverse variance weighted

### Figures

**Figure S1:** Locus zoom plot for genome-wide significant associations in the *GALNT3* locus with total body bone mineral density (generated using Musculoskeletal Knowledge Portal)

**Figure S2:** Locus zoom plot for genome-wide significant associations in the *GALNT3* locus with femoral neck mineral density (generated using Musculoskeletal Knowledge Portal)

**Figure S3:** Locus zoom plot for genome-wide significant associations in the *GALNT3* locus with lumbar spine bone mineral density (generated using Musculoskeletal Knowledge Portal)

**Figure S4:** Locus zoom plot for genome-wide significant associations in the *GALNT3* locus with type 2 diabetes (generated using Musculoskeletal Knowledge Portal)

**Figure S5:** Locus zoom plot for genome-wide significant associations in the *GALNT3* locus with type 2 diabetes, adjusted for body mass index (generated using Musculoskeletal Knowledge Portal)

## References

1. Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., and Tosteson, A. (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res* **22**, 465-475
2. Kanis, J. A., Delmas, P., Burckhardt, P., Cooper, C., and Torgerson, D. (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. *Osteoporos Int* **7**, 390-406
3. Koller, G., Goetz, V., Vandermeer, B., Homik, J., McAlister, F. A., Kendler, D., and Ye, C. (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. *Osteoporos Int*
4. McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J. Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y. C., Libanati, C., and Bone, H. G. (2014) Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med* **370**, 412-420
5. Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Prohl, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., and Mulligan, J. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. *Am J Hum Genet* **68**, 577-589
6. Staehling-Hampton, K., Prohl, S., Paeper, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D., Schatzman, R. C., Beighton, P., Papapoulos, S., Hamersma, H., and Brunkow, M. E. (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. *Am J Med Genet* **110**, 144-152
7. Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hilderling, P., Willems, P. J., Verheij, J. B., Lindpaintner, K., Vickery, B., Foerzler, D., and Van Hul, W. (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. *J Med Genet* **39**, 91-97
8. Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y. H., Duncan, E. L., Ntzani, E. E., Oei, L., Albagha, O. M. E., Amin, N., Kemp, J. P., Koller, D. L., Li, G., Liu, C. T., Minster, R. L., Moayyeri, A., Vandenput, L., Willner, D., Xiao, S. M., Yerges-Armstrong, L. M., Zheng, H. F., Alonso, N., Eriksson, J., Kammerer, C. M., Kaptoge, S. K., Leo, P. J., Thorleifsson, G., Wilson, S. G., Wilson, J. F., Aalto, V., Alen, M., Aragaki, A. K., Aspelund, T., Center, J. R., Dailiana, Z., Duggan, D. J., Garcia, M., Garcia-Giralt, N., Giroux, S., Hallmans, G., Hocking, L. J., Husted, L. B., Jameson, K. A., Khusainova, R., Kim, G. S., Kooperberg, C., Koromila, T., Kruk, M., Laaksonen, M., LaCroix, A. Z., Lee, S. H., Leung, P. C., Lewis, J. R., Masi, L., Mencej-Bedrac, S., Nguyen, T. V., Nogues, X., Patel, M. S., Prezelj, J., Rose, L. M., Scollen, S., Siggeirsdottir, K., Smith, A. V., Svensson, O., Trompet, S., Trummer, O., van Schoor, N. M., Woo, J., Zhu, K., Balcells, S., Brandi, M. L., Buckley, B. M., Cheng, S., Christiansen, C., Cooper, C., Dedoussis, G., Ford, I., Frost, M., Goltzman, D., Gonzalez-Macias, J., Kahonen, M., Karlsson, M., Khusnutdinova, E., Koh, J. M., Kollia, P., Langdahl, B. L., Leslie, W. D., Lips, P., Ljunggren, O., Lorenc, R. S., Marc, J., Mellstrom, D., Obermayer-Pietsch, B., Olmos, J. M., Pettersson-Kymmer, U., Reid, D. M., Riancho, J. A., Ridker, P. M., Rousseau, F., Jagboom, P. E., Tang, N. L. S., Urreizti, R., Van Hul, W., Viikari, J., Zarrabeitia, M. T., Aulchenko, Y. S., Castano-Betancourt, M., Grundberg, E., Herrera, L., Ingvarsson, T., Johannsdottir, H., Kwan, T., Li, R., Luben, R., Medina-Gomez, C., Th Palsson, S., Reppe, S., Rotter, J. I., Sigurdsson, G., van Meurs, J. B. J., Verlaan, D., Williams, F. M. K., Wood, A. R., Zhou, Y., Gautvik, K. M., Pastinen, T., Raychaudhuri, S., Cauley, J. A., Chasman, D. I., Clark, G. R., Cummings, S. R., Danoy, P., Dennison, E. M., Eastell, R., Eisman, J. A., Gudnason, V., Hofman, A., Jackson, R. D., Jones, G., Jukema, J. W., Khaw, K. T., Lehtimäki, T., Liu, Y., Lorentzon, M., McCloskey, E., Mitchell, B. D., Nandakumar, K., Nicholson, G. C., Oostra, B. A., Peacock, M., Pols, H. A. P., Prince, R. L., Raitakari, O., Reid, I. R., Robbins, J., Sambrook, P. N., Sham, P. C., Shuldiner, A. R., Tybavsky, F. A., van Duijn, C. M., Wareham, N.

- J., Cupples, L. A., Econs, M. J., Evans, D. M., Harris, T. B., Kung, A. W. C., Psaty, B. M., Reeve, J., Spector, T. D., Streeten, E. A., Zillikens, M. C., Thorsteinsdottir, U., Ohlsson, C., Karasik, D., Richards, J. B., Brown, M. A., Stefansson, K., Uitterlinden, A. G., Ralston, S. H., Ioannidis, J. P. A., Kiel, D. P., and Rivadeneira, F. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**, 491-501
9. Hamersma, H., Gardner, J., and Beighton, P. (2003) The natural history of sclerosteosis. *Clin Genet* **63**, 192-197
10. Gregson, C. L., and Duncan, E. L. (2020) The Genetic Architecture of High Bone Mass. *Front Endocrinol (Lausanne)* **11**, 595653
11. Gregson, C. L., Steel, S. A., O'Rourke, K. P., Allan, K., Ayuk, J., Bhalla, A., Clunie, G., Crabtree, N., Fogelman, I., Goodby, A., Langman, C. M., Linton, S., Marriott, E., McCloskey, E., Moss, K. E., Palferman, T., Panthakalam, S., Poole, K. E., Stone, M. D., Turton, J., Wallis, D., Warburton, S., Wass, J., Duncan, E. L., Brown, M. A., Davey-Smith, G., and Tobias, J. H. (2012) 'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass. *Osteoporos Int* **23**, 643-654
12. Gregson, C. L., Wheeler, L., Hardcastle, S. A., Appleton, L. H., Addison, K. A., Brugmans, M., Clark, G. R., Ward, K. A., Paggiosi, M., Stone, M., Thomas, J., Agarwal, R., Poole, K. E., McCloskey, E., Fraser, W. D., Williams, E., Bullock, A. N., Davey Smith, G., Brown, M. A., Tobias, J. H., and Duncan, E. L. (2016) Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. *J Bone Miner Res* **31**, 640-649
13. Gregson, C. L., Newell, F., Leo, P. J., Clark, G. R., Paternoster, L., Marshall, M., Forgetta, V., Morris, J. A., Ge, B., Bao, X., Duncan Bassett, J. H., Williams, G. R., Youlten, S. E., Croucher, P. I., Davey Smith, G., Evans, D. M., Kemp, J. P., Brown, M. A., Tobias, J. H., and Duncan, E. L. (2018) Genome-wide association study of extreme high bone mass: Contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes. *Bone* **114**, 62-71
14. Zankl, A., Duncan, E. L., Leo, P. J., Clark, G. R., Glazov, E. A., Addor, M. C., Herlin, T., Kim, C. A., Leheup, B. P., McGill, J., McTaggart, S., Mittas, S., Mitchell, A. L., Mortier, G. R., Robertson, S. P., Schroeder, M., Terhal, P., and Brown, M. A. (2012) Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB. *Am J Hum Genet* **90**, 494-501
15. Gregson, C. L., Bergen, D. J. M., Leo, P., Sessions, R. B., Wheeler, L., Hartley, A., Youlten, S., Croucher, P. I., McInerney-Leo, A. M., Fraser, W., Tang, J. C., Anderson, L., Marshall, M., Sergot, L., Paternoster, L., Davey Smith, G., Consortium, A., Brown, M. A., Hammond, C., Kemp, J. P., Tobias, J. H., and Duncan, E. L. (2020) A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD-Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis. *J Bone Miner Res* **35**, 92-105
16. Duncan, E. L., Danoy, P., Kemp, J. P., Leo, P. J., McCloskey, E., Nicholson, G. C., Eastell, R., Prince, R. L., Eisman, J. A., Jones, G., Sambrook, P. N., Reid, I. R., Dennison, E. M., Wark, J., Richards, J. B., Uitterlinden, A. G., Spector, T. D., Esapa, C., Cox, R. D., Brown, S. D., Thakker, R. V., Addison, K. A., Bradbury, L. A., Center, J. R., Cooper, C., Cremin, C., Estrada, K., Felsenberg, D., Gluer, C. C., Hadler, J., Henry, M. J., Hofman, A., Kotowicz, M. A., Makovey, J., Nguyen, S. C., Nguyen, T. V., Pasco, J. A., Pryce, K., Reid, D. M., Rivadeneira, F., Roux, C., Stefansson, K., Stykarsdottir, U., Thorleifsson, G., Tichawangana, R., Evans, D. M., and Brown, M. A. (2011) Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. *PLoS Genet* **7**, e1001372
17. Hartley, A., Hardcastle, S. A., Frysz, M., Parkinson, J., Paternoster, L., McCloskey, E., Poole, K. E. S., Javaid, M. K., Aye, M., Moss, K., Williams, M., Tobias, J. H., and Gregson, C. L. (2021)

- Increased development of radiographic hip osteoarthritis in individuals with high bone mass: a prospective cohort study. *Arthritis Res Ther* **23**, 4
18. McInerney-Leo, A. M., Schmidts, M., Cortes, C. R., Leo, P. J., Gener, B., Courtney, A. D., Gardiner, B., Harris, J. A., Lu, Y., Marshall, M., Consortium, U. K., Scambler, P. J., Beales, P. L., Brown, M. A., Zankl, A., Mitchison, H. M., Duncan, E. L., and Wicking, C. (2013) Short-rib polydactyly and Jeune syndromes are caused by mutations in WDR60. *Am J Hum Genet* **93**, 515-523
  19. Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alfoldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., Gauthier, L. D., Brand, H., Solomonson, M., Watts, N. A., Rhodes, D., Singer-Berk, M., England, E. M., Seaby, E. G., Kosmicki, J. A., Walters, R. K., Tashman, K., Farjoun, Y., Banks, E., Poterba, T., Wang, A., Seed, C., Whiffin, N., Chong, J. X., Samocha, K. E., Pierce-Hoffman, E., Zappala, Z., O'Donnell-Luria, A. H., Minikel, E. V., Weisburd, B., Lek, M., Ware, J. S., Vittal, C., Armean, I. M., Bergelson, L., Cibulskis, K., Connolly, K. M., Covarrubias, M., Donnelly, S., Ferriera, S., Gabriel, S., Gentry, J., Gupta, N., Jeandet, T., Kaplan, D., Llanwarne, C., Munshi, R., Novod, S., Petrillo, N., Roazen, D., Ruano-Rubio, V., Saltzman, A., Schleicher, M., Soto, J., Tibbetts, K., Tolonen, C., Wade, G., Talkowski, M. E., Genome Aggregation Database, C., Neale, B. M., Daly, M. J., and MacArthur, D. G. (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443
  20. Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., and Sunyaev, S. R. (2010) A method and server for predicting damaging missense mutations. *Nat Methods* **7**, 248-249
  21. Sim, N. L., Kumar, P., Hu, J., Henikoff, S., Schneider, G., and Ng, P. C. (2012) SIFT web server: predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res* **40**, W452-457
  22. Lopez-Ferrando, V., Gazzo, A., de la Cruz, X., Orozco, M., and Gelpi, J. L. (2017) PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update. *Nucleic Acids Res* **45**, W222-W228
  23. Schwarz, J. M., Cooper, D. N., Schuelke, M., and Seelow, D. (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* **11**, 361-362
  24. de Las Rivas, M., Paul Daniel, E. J., Narimatsu, Y., Companon, I., Kato, K., Hermosilla, P., Thureau, A., Ceballos-Laita, L., Coelho, H., Bernado, P., Marcelo, F., Hansen, L., Maeda, R., Lostao, A., Corzana, F., Clausen, H., Gerken, T. A., and Hurtado-Guerrero, R. (2020) Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. *Nat Chem Biol* **16**, 351-360
  25. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., and Schwede, T. (2018) SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* **46**, W296-W303
  26. Zheng, H. F., Forgetta, V., Hsu, Y. H., Estrada, K., Rosello-Diez, A., Leo, P. J., Dahia, C. L., Park-Min, K. H., Tobias, J. H., Kooperberg, C., Kleinman, A., Styrkarsdottir, U., Liu, C. T., Uggle, C., Evans, D. S., Nielson, C. M., Walter, K., Pettersson-Kymmer, U., McCarthy, S., Eriksson, J., Kwan, T., Jhamai, M., Trajanoska, K., Memari, Y., Min, J., Huang, J., Danecek, P., Wilmot, B., Li, R., Chou, W. C., Mokry, L. E., Moayyeri, A., Claussnitzer, M., Cheng, C. H., Cheung, W., Medina-Gomez, C., Ge, B., Chen, S. H., Choi, K., Oei, L., Fraser, J., Kraaij, R., Hibbs, M. A., Gregson, C. L., Paquette, D., Hofman, A., Wibom, C., Tranah, G. J., Marshall, M., Gardiner, B. B., Cremin, K., Auer, P., Hsu, L., Ring, S., Tung, J. Y., Thorleifsson, G., Enneman, A. W., van Schoor, N. M., de Groot, L. C., van der Velde, N., Melin, B., Kemp, J. P., Christiansen, C., Sayers, A., Zhou, Y., Calderari, S., van Rooij, J., Carlson, C., Peters, U., Berlivet, S., Dostie, J., Uitterlinden, A. G., Williams, S. R., Farber, C., Grinberg, D., LaCroix, A. Z., Haessler, J., Chasman, D. I., Giulianini, F., Rose, L. M., Ridker, P. M., Eisman, J. A., Nguyen, T. V., Center, J. R., Nogue, X., Garcia-Giralt, N., Launer, L. L., Gudnason, V., Mellstrom, D., Vandenput, L., Amin, N., van Duijn, C. M., Karlsson, M. K., Ljunggren, O., Svensson, O., Hallmans, G.,



- Rousseau, F., Giroux, S., Bussiere, J., Arp, P. P., Koromani, F., Prince, R. L., Lewis, J. R., Langdahl, B. L., Hermann, A. P., Jensen, J. E., Kaptoge, S., Khaw, K. T., Reeve, J., Formosa, M. M., Xuereb-Anastasi, A., Akesson, K., McGuigan, F. E., Garg, G., Olmos, J. M., Zarrabeitia, M. T., Riancho, J. A., Ralston, S. H., Alonso, N., Jiang, X., Goltzman, D., Pastinen, T., Grundberg, E., Gauguier, D., Orwoll, E. S., Karasik, D., Davey-Smith, G., Consortium, A., Smith, A. V., Siggeirsdottir, K., Harris, T. B., Zillikens, M. C., van Meurs, J. B., Thorsteinsdottir, U., Maurano, M. T., Timpson, N. J., Soranzo, N., Durbin, R., Wilson, S. G., Ntzani, E. E., Brown, M. A., Stefansson, K., Hinds, D. A., Spector, T., Cupples, L. A., Ohlsson, C., Greenwood, C. M., Consortium, U. K., Jackson, R. D., Rowe, D. W., Loomis, C. A., Evans, D. M., Ackert-Bicknell, C. L., Joyner, A. L., Duncan, E. L., Kiel, D. P., Rivadeneira, F., and Richards, J. B. (2015) Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. *Nature* **526**, 112-117
27. Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y. H., Duncan, E. L., Ntzani, E. E., Oei, L., Albagha, O. M., Amin, N., Kemp, J. P., Koller, D. L., Li, G., Liu, C. T., Minster, R. L., Moayyeri, A., Vandenput, L., Willner, D., Xiao, S. M., Yerges-Armstrong, L. M., Zheng, H. F., Alonso, N., Eriksson, J., Kammerer, C. M., Kaptoge, S. K., Leo, P. J., Thorleifsson, G., Wilson, S. G., Wilson, J. F., Aalto, V., Alen, M., Aragaki, A. K., Aspelund, T., Center, J. R., Dailiana, Z., Duggan, D. J., Garcia, M., Garcia-Giralt, N., Giroux, S., Hallmans, G., Hocking, L. J., Husted, L. B., Jameson, K. A., Khusainova, R., Kim, G. S., Kooperberg, C., Koromila, T., Kruk, M., Laaksonen, M., Lacroix, A. Z., Lee, S. H., Leung, P. C., Lewis, J. R., Masi, L., Mencej-Bedrac, S., Nguyen, T. V., Nogues, X., Patel, M. S., Prezelj, J., Rose, L. M., Scollen, S., Siggeirsdottir, K., Smith, A. V., Svensson, O., Trompet, S., Trummer, O., van Schoor, N. M., Woo, J., Zhu, K., Balcells, S., Brandi, M. L., Buckley, B. M., Cheng, S., Christiansen, C., Cooper, C., Dedoussis, G., Ford, I., Frost, M., Goltzman, D., Gonzalez-Macias, J., Kahonen, M., Karlsson, M., Khusnutdinova, E., Koh, J. M., Kollia, P., Langdahl, B. L., Leslie, W. D., Lips, P., Ljunggren, O., Lorenc, R. S., Marc, J., Mellstrom, D., Obermayer-Pietsch, B., Olmos, J. M., Pettersson-Kymmer, U., Reid, D. M., Riancho, J. A., Ridker, P. M., Rousseau, F., Slagboom, P. E., Tang, N. L., Urreizti, R., Van Hul, W., Viikari, J., Zarrabeitia, M. T., Aulchenko, Y. S., Castano-Betancourt, M., Grundberg, E., Herrera, L., Ingvarsson, T., Johannsdottir, H., Kwan, T., Li, R., Luben, R., Medina-Gomez, C., Palsson, S. T., Reppe, S., Rotter, J. I., Sigurdsson, G., van Meurs, J. B., Verlaan, D., Williams, F. M., Wood, A. R., Zhou, Y., Gautvik, K. M., Pastinen, T., Raychaudhuri, S., Cauley, J. A., Chasman, D. I., Clark, G. R., Cummings, S. R., Danoy, P., Dennison, E. M., Eastell, R., Eisman, J. A., Gudnason, V., Hofman, A., Jackson, R. D., Jones, G., Jukema, J. W., Khaw, K. T., Lehtimäki, T., Liu, Y., Lorentzon, M., McCloskey, E., Mitchell, B. D., Nandakumar, K., Nicholson, G. C., Oostra, B. A., Peacock, M., Pols, H. A., Prince, R. L., Raitakari, O., Reid, I. R., Robbins, J., Sambrook, P. N., Sham, P. C., Shuldiner, A. R., Tybavsky, F. A., van Duijn, C. M., Wareham, N. J., Cupples, L. A., Econs, M. J., Evans, D. M., Harris, T. B., Kung, A. W., Psaty, B. M., Reeve, J., Spector, T. D., Streeten, E. A., Zillikens, M. C., Thorsteinsdottir, U., Ohlsson, C., Karasik, D., Richards, J. B., Brown, M. A., Stefansson, K., Uitterlinden, A. G., Ralston, S. H., Ioannidis, J. P., Kiel, D. P., and Rivadeneira, F. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**, 491-501
28. Kemp, J. P., Morris, J. A., Medina-Gomez, C., Forgetta, V., Warrington, N. M., Youlten, S. E., Zheng, J., Gregson, C. L., Grundberg, E., Trajanoska, K., Logan, J. G., Pollard, A. S., Sparkes, P. C., Gherardello, E. J., Allen, R., Leitch, V. D., Butterfield, N. C., Komla-Ebri, D., Adoum, A. T., Curry, K. F., White, J. K., Kussy, F., Greenlaw, K. M., Xu, C., Harvey, N. C., Cooper, C., Adams, D. J., Greenwood, C. M. T., Maurano, M. T., Kaptoge, S., Rivadeneira, F., Tobias, J. H., Croucher, P. I., Ackert-Bicknell, C. L., Bassett, J. H. D., Williams, G. R., Richards, J. B., and Evans, D. M. (2017) Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. *Nat Genet* **49**, 1468-1475
29. Morris, J. A., Kemp, J. P., Youlten, S. E., Laurent, L., Logan, J. G., Chai, R. C., Vulpesu, N. A., Forgetta, V., Kleinman, A., Mohanty, S. T., Sergio, C. M., Quinn, J., Nguyen-Yamamoto, L.,

- Luco, A. L., Vijay, J., Simon, M. M., Pramatarova, A., Medina-Gomez, C., Trajanoska, K., Ghirardello, E. J., Butterfield, N. C., Curry, K. F., Leitch, V. D., Sparkes, P. C., Adoum, A. T., Mannan, N. S., Komla-Ebri, D. S. K., Pollard, A. S., Dewhurst, H. F., Hassall, T. A. D., Beltejar, M. G., and Me Research, T., Adams, D. J., Vaillancourt, S. M., Kaptoge, S., Baldock, P., Cooper, C., Reeve, J., Ntzani, E. E., Evangelou, E., Ohlsson, C., Karasik, D., Rivadeneira, F., Kiel, D. P., Tobias, J. H., Gregson, C. L., Harvey, N. C., Grundberg, E., Goltzman, D., Adams, D. J., Lelliott, C. J., Hinds, D. A., Ackert-Bicknell, C. L., Hsu, Y. H., Maurano, M. T., Croucher, P. I., Williams, G. R., Bassett, J. H. D., Evans, D. M., and Richards, J. B. (2019) An atlas of genetic influences on osteoporosis in humans and mice. *Nat Genet* **51**, 258-266
30. Kiel, D. P., Kemp, J. P., Rivadeneira, F., Westendorp, J. J., Karasik, D., Duncan, E. L., Imai, Y., Muller, R., Flannick, J., Bonewald, L., and Burtt, N. (2020) The Musculoskeletal Knowledge Portal: Making Omics Data Useful to the Broader Scientific Community. *J Bone Miner Res* **35**, 1626-1633
  31. Watanabe, K., Stringer, S., Frei, O., Umicevic Mirkov, M., de Leeuw, C., Polderman, T. J. C., van der Sluis, S., Andreassen, O. A., Neale, B. M., and Posthuma, D. (2019) A global overview of pleiotropy and genetic architecture in complex traits. *Nat Genet* **51**, 1339-1348
  32. Grundberg, E., Kwan, T., Ge, B., Lam, K. C., Koka, V., Kindmark, A., Mallmin, H., Dias, J., Verlaan, D. J., Ouimet, M., Sinnett, D., Rivadeneira, F., Estrada, K., Hofman, A., van Meurs, J. M., Uitterlinden, A., Beaulieu, P., Graziani, A., Harmsen, E., Ljunggren, O., Ohlsson, C., Mellstrom, D., Karlsson, M. K., Nilsson, O., and Pastinen, T. (2009) Population genomics in a disease targeted primary cell model. *Genome Res* **19**, 1942-1952
  33. Medina-Gomez, C., Kemp, J. P., Trajanoska, K., Luan, J., Chesi, A., Ahluwalia, T. S., Mook-Kanamori, D. O., Ham, A., Hartwig, F. P., Evans, D. S., Joro, R., Nedeljkovic, I., Zheng, H. F., Zhu, K., Atalay, M., Liu, C. T., Nethander, M., Broer, L., Porleifsson, G., Mullin, B. H., Handelman, S. K., Nalls, M. A., Jessen, L. E., Heppe, D. H. M., Richards, J. B., Wang, C., Chawes, B., Schraut, K. E., Amin, N., Wareham, N., Karasik, D., Van der Velde, N., Ikram, M. A., Zemel, B. S., Zhou, Y., Carlsson, C. J., Liu, Y., McGuigan, F. E., Boer, C. G., Bonnelykke, K., Ralston, S. H., Robbins, J. A., Walsh, J. P., Zillikens, M. C., Langenberg, C., Li-Gao, R., Williams, F. M. K., Harris, T. B., Akesson, K., Jackson, R. D., Sigurdsson, G., den Heijer, M., van der Eerden, B. C. J., van de Peppel, J., Spector, T. D., Pennell, C., Horta, B. L., Felix, J. F., Zhao, J. H., Wilson, S. G., de Mutsert, R., Bisgaard, H., Stykarsdottir, U., Jaddoe, V. W., Orwoll, E., Lakka, T. A., Scott, R., Grant, S. F. A., Lorentzon, M., van Duijn, C. M., Wilson, J. F., Stefansson, K., Psaty, B. M., Kiel, D. P., Ohlsson, C., Ntzani, E., van Wijnen, A. J., Forgetta, V., Ghanbari, M., Logan, J. G., Williams, G. R., Bassett, J. H. D., Croucher, P. I., Evangelou, E., Uitterlinden, A. G., Ackert-Bicknell, C. L., Tobias, J. H., Evans, D. M., and Rivadeneira, F. (2018) Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. *Am J Hum Genet* **102**, 88-102
  34. Burgess, S., Small, D. S., and Thompson, S. G. (2017) A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* **26**, 2333-2355
  35. Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Sheehan, N., and Thompson, J. (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* **36**, 1783-1802
  36. Zhu, Z., Zheng, Z., Zhang, F., Wu, Y., Trzaskowski, M., Maier, R., Robinson, M. R., McGrath, J. J., Visscher, P. M., Wray, N. R., and Yang, J. (2018) Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun* **9**, 224
  37. Esapa, C. T., Head, R. A., Jeyabalan, J., Evans, H., Hough, T. A., Cheeseman, M. T., McNally, E. G., Carr, A. J., Thomas, G. P., Brown, M. A., Croucher, P. I., Brown, S. D., Cox, R. D., and Thakker, R. V. (2012) A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis. *PLoS One* **7**, e43205

38. Masi, L., Beltrami, G., Ottanelli, S., Franceschelli, F., Gozzini, A., Zonefrati, R., Galli, G., Ciuffi, S., Mavilia, C., Giusti, F., Marcucci, G., Cioppi, F., Colli, E., Fossi, C., Franchi, A., Casentini, C., Capanna, R., and Brandi, M. L. (2015) Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization. *Calcif Tissue Int* **96**, 438-452
39. Ramnitz, M. S., Gourh, P., Goldbach-Mansky, R., Wodajo, F., Ichikawa, S., Econs, M. J., White, K. E., Molinolo, A., Chen, M. Y., Heller, T., Del Rivero, J., Seo-Mayer, P., Arabshahi, B., Jackson, M. B., Hatab, S., McCarthy, E., Guthrie, L. C., Brillante, B. A., Gafni, R. I., and Collins, M. T. (2016) Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. *J Bone Miner Res* **31**, 1845-1854
40. Topaz, O., Shurman, D. L., Bergman, R., Indelman, M., Ratajczak, P., Mizrachi, M., Khamaysi, Z., Behar, D., Petronius, D., Friedman, V., Zelikovic, I., Raimer, S., Metzker, A., Richard, G., and Sprecher, E. (2004) Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. *Nat Genet* **36**, 579-581
41. Kato, K., Hansen, L., and Clausen, H. (2021) Polypeptide N-acetylgalactosaminyltransferase-Associated Phenotypes in Mammals. *Molecules* **26**
42. Frishberg, Y., Ito, N., Rinat, C., Yamazaki, Y., Feinstein, S., Urakawa, I., Navon-Elkan, P., Becker-Cohen, R., Yamashita, T., Araya, K., Igarashi, T., Fujita, T., and Fukumoto, S. (2007) Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. *J Bone Miner Res* **22**, 235-242
43. Ito, N., and Fukumoto, S. (2021) Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. *Calcif Tissue Int* **108**, 104-115
44. Campagnoli, M. F., Pucci, A., Garelli, E., Carando, A., Defilippi, C., Lala, R., Ingrosso, G., Dianzani, I., Forni, M., and Ramenghi, U. (2006) Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. *J Clin Pathol* **59**, 440-442
45. Joseph, L., Hing, S. N., Presneau, N., O'Donnell, P., Diss, T., Idowu, B. D., Joseph, S., Flanagan, A. M., and Delaney, D. (2010) Familial tumoral calcinosis and hyperostosis-hyperphosphatemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. *Skeletal Radiol* **39**, 63-68
46. Ichikawa, S., Lyles, K. W., and Econs, M. J. (2005) A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. *J Clin Endocrinol Metab* **90**, 2420-2423
47. King, E. A., Davis, J. W., and Degner, J. F. (2019) Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLoS Genet* **15**, e1008489
48. Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., Cardon, L. R., Whittaker, J. C., and Sanseau, P. (2015) The support of human genetic evidence for approved drug indications. *Nat Genet* **47**, 856-860
49. Hartley, A., Hardcastle, S. A., Paternoster, L., McCloskey, E., Poole, K. E. S., Javaid, M. K., Aye, M., Moss, K., Granell, R., Gregory, J., Williams, M., Tobias, J. H., and Gregson, C. L. (2020) Individuals with high bone mass have increased progression of radiographic and clinical features of knee osteoarthritis. *Osteoarthritis Cartilage* **28**, 1180-1190
50. Hardcastle, S. A., Dieppe, P., Gregson, C. L., Hunter, D., Thomas, G. E., Arden, N. K., Spector, T. D., Hart, D. J., Laugharne, M. J., Clague, G. A., Edwards, M. H., Dennison, E. M., Cooper, C., Williams, M., Davey Smith, G., and Tobias, J. H. (2014) Prevalence of radiographic hip osteoarthritis is increased in high bone mass. *Osteoarthritis Cartilage* **22**, 1120-1128
51. Leupin, O., Piters, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Fuentes, F. J., Itin, P. H., Boudin, E., de Freitas, F., Jennes, K., Brannetti,



- B., Charara, N., Ebersbach, H., Geisse, S., Lu, C. X., Bauer, A., Van Hul, W., and Kneissel, M. (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. *J Biol Chem* **286**, 19489-19500
52. Gregson, C. L., Paggiosi, M. A., Crabtree, N., Steel, S. A., McCloskey, E., Duncan, E. L., Fan, B., Shepherd, J. A., Fraser, W. D., Smith, G. D., and Tobias, J. H. (2013) Analysis of body composition in individuals with high bone mass reveals a marked increase in fat mass in women but not men. *J Clin Endocrinol Metab* **98**, 818-828
  53. Frost, M., Andersen, T., Gossiel, F., Hansen, S., Bollerslev, J., van Hul, W., Eastell, R., Kassem, M., and Brixen, K. (2011) Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. *J Bone Miner Res* **26**, 1721-1728
  54. Balemans, W., Devogelaer, J. P., Cleiren, E., Piters, E., Caussin, E., and Van Hul, W. (2007) Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. *J Bone Miner Res* **22**, 708-716
  55. Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., and Lifton, R. P. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. *N Engl J Med* **346**, 1513-1521.
  56. Whyte, M. P., Reinus, W. H., and Mumm, S. (2004) High-bone-mass disease and LRP5. *N Engl J Med* **350**, 2096-2099; author reply 2096-2099
  57. Gok, F., Chefetz, I., Indelman, M., Kocaoglu, M., and Sprecher, E. (2009) Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome. *Acta Orthop* **80**, 131-134
  58. Garringer, H. J., Mortazavi, S. M., Esteghamat, F., Malekpour, M., Boztepe, H., Tanakol, R., Davis, S. I., and White, K. E. (2007) Two novel GALNT3 mutations in familial tumoral calcinosis. *Am J Med Genet A* **143A**, 2390-2396
  59. Kislakinci, R. M., Gurbuz, F., Balci, S., Bisgin, A., Tastan, M., Yuksel, B., and Yilmaz, M. (2019) Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey. *J Clin Res Pediatr Endocrinol* **11**, 94-99
  60. Demellawy, D. E., Chang, N., de Nanassy, J., and Nasr, A. (2015) GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis. *Scand J Rheumatol* **44**, 170-172
  61. Carmichael, K. D., Bynum, J. A., and Evans, E. B. (2009) Familial tumoral calcinosis: a forty-year follow-up on one family. *J Bone Joint Surg Am* **91**, 664-671
  62. Finer, G., Price, H. E., Shore, R. M., White, K. E., and Langman, C. B. (2014) Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. *Am J Med Genet A* **164A**, 1545-1549
  63. Ichikawa, S., Baujat, G., Seyahi, A., Garoufali, A. G., Imel, E. A., Padgett, L. R., Austin, A. M., Sorenson, A. H., Pejin, Z., Topouchian, V., Quartier, P., Cormier-Daire, V., Dechaux, M., Malandrino, F., Singhellakis, P. N., Le Merrer, M., and Econs, M. J. (2010) Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. *Am J Med Genet A* **152A**, 896-903
  64. Laleye, A., Alao, M. J., Gbessi, G., Adjagba, M., Marche, M., Couprie, I., Redonnet-Vernhet, I., Lepreux, S., Ayivi, B., Darboux, R. B., Lacombe, D., and Arveiler, B. (2008) Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family. *Genet Couns* **19**, 183-192
  65. Sun, L., Zhao, L., Du, L., Zhang, P., Zhang, M., Li, M., Liu, T., Ye, L., Tao, B., Zhao, H., Liu, J., and Ding, X. (2016) Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis. *Bone Res* **4**, 16038
  66. Dauchez, A., Souffir, C., Quartier, P., Baujat, G., Briot, K., and Roux, C. (2019) Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti-Interleukin-1 Treatments. *JBMR Plus* **3**, e10185

67. Guerra, M. G., Videira, T., de Fonseca, D., Vieira, R., Dos Santos, J., and Pinto, S. (2020) Hyperphosphataemic familial tumoral calcinosis: case report of a rare and challenging disease. *Scand J Rheumatol* **49**, 80-81
68. Rafaelsen, S., Johansson, S., Raeder, H., and Bjerknes, R. (2014) Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature. *BMC Genet* **15**, 98
69. Mahjoubi, F., Ghadir, M., Samanian, S., Heydari, I., and Honardoost, M. (2020) Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene. *J Endocrinol Invest* **43**, 1125-1130
70. Ichikawa, S., Guignon, V., Imel, E. A., Courouble, M., Heissat, S., Henley, J. D., Sorenson, A. H., Petit, B., Lienhardt, A., and Econs, M. J. (2007) Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. *J Clin Endocrinol Metab* **92**, 1943-1947
71. Ichikawa, S., Imel, E. A., Sorenson, A. H., Severe, R., Knudson, P., Harris, G. J., Shaker, J. L., and Econs, M. J. (2006) Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. *J Clin Endocrinol Metab* **91**, 4472-4475
72. Barbieri, A. M., Filopanti, M., Bua, G., and Beck-Peccoz, P. (2007) Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis. *J Hum Genet* **52**, 464-468
73. Yancovitch, A., HersHKovitz, D., Indelman, M., Galloway, P., Whiteford, M., Sprecher, E., and Kilic, E. (2011) Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. *J Bone Miner Metab* **29**, 621-625
74. Dumitrescu, C. E., Kelly, M. H., Khosravi, A., Hart, T. C., Brahim, J., White, K. E., Farrow, E. G., Nathan, M. H., Murphey, M. D., and Collins, M. T. (2009) A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. *Osteoporos Int* **20**, 1273-1278
75. Olauson, H., Krajisnik, T., Larsson, C., Lindberg, B., and Larsson, T. E. (2008) A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. *Eur J Endocrinol* **158**, 929-934
76. Frishberg, Y., Topaz, O., Bergman, R., Behar, D., Fisher, D., Gordon, D., Richard, G., and Sprecher, E. (2005) Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. *J Mol Med (Berl)* **83**, 33-38
77. Dayal, D., Gupta, S., Kumar, R., Srinivasan, R., Lorenz-Depiereux, B., and Strom, T. M. (2021) A novel homozygous variant in exon 10 of the GALNT3 gene causing hyperphosphatemic familial tumoral calcinosis in a family from North India. *Intractable Rare Dis Res* **10**, 55-57
78. Specktor, P., Cooper, J. G., Indelman, M., and Sprecher, E. (2006) Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. *J Hum Genet* **51**, 487-490
79. Bonas-Guarch, S., Guindo-Martinez, M., Miguel-Escalada, I., Grarup, N., Sebastian, D., Rodriguez-Fos, E., Sanchez, F., Planas-Felix, M., Cortes-Sanchez, P., Gonzalez, S., Timshel, P., Pers, T. H., Morgan, C. C., Moran, I., Atla, G., Gonzalez, J. R., Puiggros, M., Marti, J., Andersson, E. A., Diaz, C., Badia, R. M., Udler, M., Leong, A., Kaur, V., Flannick, J., Jorgensen, T., Linneberg, A., Jorgensen, M. E., Witte, D. R., Christensen, C., Brandslund, I., Appel, E. V., Scott, R. A., Luan, J., Langenberg, C., Wareham, N. J., Pedersen, O., Zorzano, A., Florez, J. C., Hansen, T., Ferrer, J., Mercader, J. M., and Torrents, D. (2018) Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. *Nat Commun* **9**, 321

80. Chen, J., Sun, M., Adeyemo, A., Pirie, F., Carstensen, T., Pomilla, C., Doumatey, A. P., Chen, G., Young, E. H., Sandhu, M., Morris, A. P., Barroso, I., McCarthy, M. I., Mahajan, A., Wheeler, E., Rotimi, C. N., and Motala, A. A. (2019) Genome-wide association study of type 2 diabetes in Africa. *Diabetologia* **62**, 1204-1211
81. Chen, P., Ong, R. T., Tay, W. T., Sim, X., Ali, M., Xu, H., Suo, C., Liu, J., Chia, K. S., Vithana, E., Young, T. L., Aung, T., Lim, W. Y., Khor, C. C., Cheng, C. Y., Wong, T. Y., Teo, Y. Y., and Tai, E. S. (2013) A study assessing the association of glycated hemoglobin A1C (HbA1C) associated variants with HbA1C, chronic kidney disease and diabetic retinopathy in populations of Asian ancestry. *PLoS One* **8**, e79767
82. Consortium, S. T. D., Williams, A. L., Jacobs, S. B., Moreno-Macias, H., Huerta-Chagoya, A., Churchhouse, C., Marquez-Luna, C., Garcia-Ortiz, H., Gomez-Vazquez, M. J., Burt, N. P., Aguilar-Salinas, C. A., Gonzalez-Villalpando, C., Florez, J. C., Orozco, L., Haiman, C. A., Tusie-Luna, T., and Altshuler, D. (2014) Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. *Nature* **506**, 97-101
83. Mercader, J. M., Liao, R. G., Bell, A. D., Dymek, Z., Estrada, K., Tukiainen, T., Huerta-Chagoya, A., Moreno-Macias, H., Jablonski, K. A., Hanson, R. L., Walford, G. A., Moran, I., Chen, L., Agarwala, V., Ordonez-Sanchez, M. L., Rodriguez-Guillen, R., Rodriguez-Torres, M., Segura-Kato, Y., Garcia-Ortiz, H., Centeno-Cruz, F., Barajas-Olmos, F., Caulkins, L., Puppala, S., Fontanillas, P., Williams, A. L., Bonas-Guarch, S., Hartl, C., Ripke, S., Diabetes Prevention Program Research, G., Tooley, K., Lane, J., Zerrweck, C., Martinez-Hernandez, A., Cordova, E. J., Mendoza-Caamal, E., Contreras-Cubas, C., Gonzalez-Villalpando, M. E., Cruz-Bautista, I., Munoz-Hernandez, L., Gomez-Velasco, D., Alvirde, U., Henderson, B. E., Wilkens, L. R., Le Marchand, L., Arellano-Campos, O., Riba, L., Harden, M., Broad Genomics, P., Gabriel, S., Consortium, T. D. G., Abboud, H. E., Cortes, M. L., Revilla-Monsalve, C., Islas-Andrade, S., Soberon, X., Curran, J. E., Jenkinson, C. P., DeFronzo, R. A., Lehman, D. M., Hanis, C. L., Bell, G. I., Boehnke, M., Blangero, J., Duggirala, R., Saxena, R., MacArthur, D., Ferrer, J., McCarroll, S. A., Torrents, D., Knowler, W. C., Baier, L. J., Burt, N., Gonzalez-Villalpando, C., Haiman, C. A., Aguilar-Salinas, C. A., Tusie-Luna, T., Flannick, J., Jacobs, S. B. R., Orozco, L., Altshuler, D., Florez, J. C., and Consortium, S. T. D. G. (2017) A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. *Diabetes* **66**, 2903-2914
84. Flannick, J., Fuchsberger, C., Mahajan, A., Teslovich, T. M., Agarwala, V., Gaulton, K. J., Caulkins, L., Koesterer, R., Ma, C., Moutsianas, L., McCarthy, D. J., Rivas, M. A., Perry, J. R. B., Sim, X., Blackwell, T. W., Robertson, N. R., Rayner, N. W., Cingolani, P., Locke, A. E., Tajas, J. F., Highland, H. M., Dupuis, J., Chines, P. S., Lindgren, C. M., Hartl, C., Jackson, A. U., Chen, H., Huyghe, J. R., van de Bunt, M., Pearson, R. D., Kumar, A., Muller-Nurasyid, M., Grarup, N., Stringham, H. M., Gamazon, E. R., Lee, J., Chen, Y., Scott, R. A., Below, J. E., Chen, P., Huang, J., Go, M. J., Stitzel, M. L., Pasko, D., Parker, S. C. J., Varga, T. V., Green, T., Beer, N. L., Day-Williams, A. G., Ferreira, T., Fingerlin, T., Horikoshi, M., Hu, C., Huh, I., Ikram, M. K., Kim, B. J., Kim, Y., Kim, Y. J., Kwon, M. S., Lee, J., Lee, S., Lin, K. H., Maxwell, T. J., Nagai, Y., Wang, X., Welch, R. P., Yoon, J., Zhang, W., Barzilai, N., Voight, B. F., Han, B. G., Jenkinson, C. P., Kuulasmaa, T., Kuusisto, J., Manning, A., Ng, M. C. Y., Palmer, N. D., Balkau, B., Stancakova, A., Abboud, H. E., Boeing, H., Giedraitis, V., Prabhakaran, D., Gottesman, O., Scott, J., Carey, J., Kwan, P., Grant, G., Smith, J. D., Neale, B. M., Purcell, S., Butterworth, A. S., Howson, J. M. M., Lee, H. M., Lu, Y., Kwak, S. H., Zhao, W., Danesh, J., Lam, V. K. L., Park, K. S., Saleheen, D., So, W. Y., Tam, C. H. T., Afzal, U., Aguilar, D., Arya, R., Aung, T., Chan, E., Navarro, C., Cheng, C. Y., Palli, D., Correa, A., Curran, J. E., Rybin, D., Farook, V. S., Fowler, S. P., Freedman, B. I., Griswold, M., Hale, D. E., Hicks, P. J., Khor, C. C., Kumar, S., Lehne, B., Thuillier, D., Lim, W. Y., Liu, J., Loh, M., Musani, S. K., Puppala, S., Scott, W. R., Yengo, L., Tan, S. T., Taylor, H. A., Thameem, F., Wilson, G., Wong, T. Y., Njolstad, P. R., Levy, J. C., Mangino, M., Bonnycastle, L. L., Schwarzmayr, T., Fadista, J., Surdulescu, G. L., Herder, C., Groves, C. J., Wieland, T., Bork-Jensen, J., Brandslund, I., Christensen, C., Koistinen, H. A., Doney, A. S. F., Kinnunen, L., Esko,

- T., Farmer, A. J., Hakaste, L., Hodgkiss, D., Kravic, J., Lyssenko, V., Hollensted, M., Jorgensen, M. E., Jorgensen, T., Ladenvall, C., Justesen, J. M., Karajamaki, A., Kriebel, J., Rathmann, W., Lannfelt, L., Lauritzen, T., Narisu, N., Linneberg, A., Melander, O., Milani, L., Neville, M., Orho-Melander, M., Qi, L., Qi, Q., Roden, M., Rolandsson, O., Swift, A., Rosengren, A. H., Stirrups, K., Wood, A. R., Mihailov, E., Blancher, C., Carneiro, M. O., Maguire, J., Poplin, R., Shakir, K., Fennell, T., DePristo, M., de Angelis, M. H., Deloukas, P., Gjesing, A. P., Jun, G., Nilsson, P., Murphy, J., Onofrio, R., Thorand, B., Hansen, T., Meisinger, C., Hu, F. B., Isomaa, B., Karpe, F., Liang, L., Peters, A., Huth, C., O'Rahilly, S. P., Palmer, C. N. A., Pedersen, O., Rauramaa, R., Tuomilehto, J., Salomaa, V., Watanabe, R. M., Syvanen, A. C., Bergman, R. N., Bharadwaj, D., Bottinger, E. P., Cho, Y. S., Chandak, G. R., Chan, J. C., Chia, K. S., Daly, M. J., Ebrahim, S. B., Langenberg, C., Elliott, P., Jablonski, K. A., Lehman, D. M., Jia, W., Ma, R. C. W., Pollin, T. I., Sandhu, M., Tandon, N., Froguel, P., Barroso, I., Teo, Y. Y., Zeggini, E., Loos, R. J. F., Small, K. S., Ried, J. S., DeFronzo, R. A., Grallert, H., Glaser, B., Metspalu, A., Wareham, N. J., Walker, M., Banks, E., Gieger, C., Ingelsson, E., Im, H. K., Illig, T., Franks, P. W., Buck, G., Trakalo, J., Buck, D., Prokopenko, I., Magi, R., Lind, L., Farjoun, Y., Owen, K. R., Gloyn, A. L., Strauch, K., Tuomi, T., Kooner, J. S., Lee, J. Y., Park, T., Donnelly, P., Morris, A. D., Hattersley, A. T., Bowden, D. W., Collins, F. S., Atzmon, G., Chambers, J. C., Spector, T. D., Laakso, M., Strom, T. M., Bell, G. I., Blangero, J., Duggirala, R., Tai, E. S., McVean, G., Hanis, C. L., Wilson, J. G., Seielstad, M., Frayling, T. M., Meigs, J. B., Cox, N. J., Sladek, R., Lander, E. S., Gabriel, S., Mohlke, K. L., Meitinger, T., Groop, L., Abecasis, G., Scott, L. J., Morris, A. P., Kang, H. M., Altshuler, D., Burt, N. P., Florez, J. C., Boehnke, M., and McCarthy, M. I. (2017) Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. *Sci Data* **4**, 170179
85. Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., Ma, C., Fontanillas, P., Moutsianas, L., McCarthy, D. J., Rivas, M. A., Perry, J. R. B., Sim, X., Blackwell, T. W., Robertson, N. R., Rayner, N. W., Cingolani, P., Locke, A. E., Tajas, J. F., Highland, H. M., Dupuis, J., Chines, P. S., Lindgren, C. M., Hartl, C., Jackson, A. U., Chen, H., Huyghe, J. R., van de Bunt, M., Pearson, R. D., Kumar, A., Muller-Nurasyid, M., Grarup, N., Stringham, H. M., Gamazon, E. R., Lee, J., Chen, Y., Scott, R. A., Below, J. E., Chen, P., Huang, J., Go, M. J., Stitzel, M. L., Pasko, D., Parker, S. C. J., Varga, T. V., Green, T., Beer, N. L., Day-Williams, A. G., Ferreira, T., Fingerlin, T., Horikoshi, M., Hu, C., Huh, I., Ikram, M. K., Kim, B. J., Kim, Y., Kim, Y. J., Kwon, M. S., Lee, J., Lee, S., Lin, K. H., Maxwell, T. J., Nagai, Y., Wang, X., Welch, R. P., Yoon, J., Zhang, W., Barzilai, N., Voight, B. F., Han, B. G., Jenkinson, C. P., Kuulasmaa, T., Kuusisto, J., Manning, A., Ng, M. C. Y., Palmer, N. D., Balkau, B., Stancakova, A., Abboud, H. E., Boeing, H., Giedraitis, V., Prabhakaran, D., Gottesman, O., Scott, J., Carey, J., Kwan, P., Grant, G., Smith, J. D., Neale, B. M., Purcell, S., Butterworth, A. S., Howson, J. M. M., Lee, H. M., Lu, Y., Kwak, S. H., Zhao, W., Danesh, J., Lam, V. K. L., Park, K. S., Saleheen, D., So, W. Y., Tam, C. H. T., Afzal, U., Aguilar, D., Arya, R., Aung, T., Chan, E., Navarro, C., Cheng, C. Y., Palli, D., Correa, A., Curran, J. E., Rybin, D., Farook, V. S., Fowler, S. P., Freedman, B. I., Griswold, M., Hale, D. E., Hicks, P. J., Khor, C. C., Kumar, S., Lehne, B., Thuillier, D., Lim, W. Y., Liu, J., van der Schouw, Y. T., Loh, M., Musani, S. K., Puppala, S., Scott, W. R., Yengo, L., Tan, S. T., Taylor, H. A., Jr., Thameem, F., Wilson, G., Sr., Wong, T. Y., Njolstad, P. R., Levy, J. C., Mangino, M., Bonnycastle, L. L., Schwarzmayer, T., Fadista, J., Surdulescu, G. L., Herder, C., Groves, C. J., Wieland, T., Bork-Jensen, J., Brandslund, I., Christensen, C., Koistinen, H. A., Doney, A. S. F., Kinnunen, L., Esko, T., Farmer, A. J., Hakaste, L., Hodgkiss, D., Kravic, J., Lyssenko, V., Hollensted, M., Jorgensen, M. E., Jorgensen, T., Ladenvall, C., Justesen, J. M., Karajamaki, A., Kriebel, J., Rathmann, W., Lannfelt, L., Lauritzen, T., Narisu, N., Linneberg, A., Melander, O., Milani, L., Neville, M., Orho-Melander, M., Qi, L., Qi, Q., Roden, M., Rolandsson, O., Swift, A., Rosengren, A. H., Stirrups, K., Wood, A. R., Mihailov, E., Blancher, C., Carneiro, M. O., Maguire, J., Poplin, R., Shakir, K., Fennell, T., DePristo, M., de Angelis, M. H., Deloukas, P., Gjesing, A. P., Jun, G., Nilsson, P., Murphy, J., Onofrio, R., Thorand, B.,



- Hansen, T., Meisinger, C., Hu, F. B., Isomaa, B., Karpe, F., Liang, L., Peters, A., Huth, C., O'Rahilly, S. P., Palmer, C. N. A., Pedersen, O., Rauramaa, R., Tuomilehto, J., Salomaa, V., Watanabe, R. M., Syvanen, A. C., Bergman, R. N., Bharadwaj, D., Bottinger, E. P., Cho, Y. S., Chandak, G. R., Chan, J. C. N., Chia, K. S., Daly, M. J., Ebrahim, S. B., Langenberg, C., Elliott, P., Jablonski, K. A., Lehman, D. M., Jia, W., Ma, R. C. W., Pollin, T. I., Sandhu, M., Tandon, N., Froguel, P., Barroso, I., Teo, Y. Y., Zeggini, E., Loos, R. J. F., Small, K. S., Ried, J. S., DeFronzo, R. A., Grallert, H., Glaser, B., Metspalu, A., Wareham, N. J., Walker, M., Banks, E., Gieger, C., Ingelsson, E., Im, H. K., Illig, T., Franks, P. W., Buck, G., Trakalo, J., Buck, D., Prokopenko, I., Magi, R., Lind, L., Farjoun, Y., Owen, K. R., Gloyn, A. L., Strauch, K., Tuomi, T., Kooner, J. S., Lee, J. Y., Park, T., Donnelly, P., Morris, A. D., Hattersley, A. T., Bowden, D. W., Collins, F. S., Atzmon, G., Chambers, J. C., Spector, T. D., Laakso, M., Strom, T. M., Bell, G. I., Blangero, J., Duggirala, R., Tai, E. S., McVean, G., Hanis, C. L., Wilson, J. G., Seielstad, M., Frayling, T. M., Meigs, J. B., Cox, N. J., Sladek, R., Lander, E. S., Gabriel, S., Burt, N. P., Mohlke, K. L., Meitinger, T., Groop, L., Abecasis, G., Florez, J. C., Scott, L. J., Morris, A. P., Kang, H. M., Boehnke, M., Altshuler, D., and McCarthy, M. I. (2016) The genetic architecture of type 2 diabetes. *Nature* **536**, 41-47
86. Gaulton, K. J., Ferreira, T., Lee, Y., Raimondo, A., Magi, R., Reschen, M. E., Mahajan, A., Locke, A., Rayner, N. W., Robertson, N., Scott, R. A., Prokopenko, I., Scott, L. J., Green, T., Sparso, T., Thuillier, D., Yengo, L., Grallert, H., Wahl, S., Franberg, M., Strawbridge, R. J., Kestler, H., Chheda, H., Eisele, L., Gustafsson, S., Steinthorsdottir, V., Thorleifsson, G., Qi, L., Karssen, L. C., van Leeuwen, E. M., Willems, S. M., Li, M., Chen, H., Fuchsberger, C., Kwan, P., Ma, C., Linderman, M., Lu, Y., Thomsen, S. K., Rundle, J. K., Beer, N. L., van de Bunt, M., Chalisey, A., Kang, H. M., Voight, B. F., Abecasis, G. R., Almgren, P., Baldassarre, D., Balkau, B., Benediktsson, R., Bluher, M., Boeing, H., Bonnycastle, L. L., Bottinger, E. P., Burt, N. P., Carey, J., Charpentier, G., Chines, P. S., Cornelis, M. C., Couper, D. J., Crenshaw, A. T., van Dam, R. M., Doney, A. S., Dorkhan, M., Edkins, S., Eriksson, J. G., Esko, T., Eury, E., Fadista, J., Flannick, J., Fontanillas, P., Fox, C., Franks, P. W., Gertow, K., Gieger, C., Gigante, B., Gottesman, O., Grant, G. B., Grarup, N., Groves, C. J., Hassinen, M., Have, C. T., Herder, C., Holmen, O. L., Hreidarsson, A. B., Humphries, S. E., Hunter, D. J., Jackson, A. U., Jonsson, A., Jorgensen, M. E., Jorgensen, T., Kao, W. H., Kerrison, N. D., Kinnunen, L., Klopp, N., Kong, A., Kovacs, P., Kraft, P., Kravic, J., Langford, C., Leander, K., Liang, L., Lichtner, P., Lindgren, C. M., Lindholm, E., Linneberg, A., Liu, C. T., Lobbens, S., Luan, J., Lyssenko, V., Mannisto, S., McLeod, O., Meyer, J., Mihailov, E., Mirza, G., Muhleisen, T. W., Muller-Nurasyid, M., Navarro, C., Nothen, M. M., Oskolkov, N. N., Owen, K. R., Palli, D., Pechlivanis, S., Peltonen, L., Perry, J. R., Platou, C. G., Roden, M., Ruderfer, D., Rybin, D., van der Schouw, Y. T., Sennblad, B., Sigurdsson, G., Stancakova, A., Steinbach, G., Storm, P., Strauch, K., Stringham, H. M., Sun, Q., Thorand, B., Tikkanen, E., Tonjes, A., Trakalo, J., Tremoli, E., Tuomi, T., Wennauer, R., Wiltshire, S., Wood, A. R., Zeggini, E., Dunham, I., Birney, E., Pasquali, L., Ferrer, J., Loos, R. J., Dupuis, J., Florez, J. C., Boerwinkle, E., Pankow, J. S., van Duijn, C., Sijbrands, E., Meigs, J. B., Hu, F. B., Thorsteinsdottir, U., Stefansson, K., Lakka, T. A., Rauramaa, R., Stumvoll, M., Pedersen, N. L., Lind, L., Keinanen-Kiukkaanniemi, S. M., Korpi-Hyovalti, E., Saaristo, T. E., Saltevo, J., Kuusisto, J., Laakso, M., Metspalu, A., Erbel, R., Jocke, K. H., Moebus, S., Ripatti, S., Salomaa, V., Ingelsson, E., Boehm, B. O., Bergman, R. N., Collins, F. S., Mohlke, K. L., Koistinen, H., Tuomilehto, J., Hveem, K., Njolstad, I., Deloukas, P., Donnelly, P. J., Frayling, T. M., Hattersley, A. T., de Faire, U., Hamsten, A., Illig, T., Peters, A., Cauchi, S., Sladek, R., Froguel, P., Hansen, T., Pedersen, O., Morris, A. D., Palmer, C. N., Kathiresan, S., Melander, O., Nilsson, P. M., Groop, L. C., Barroso, I., Langenberg, C., Wareham, N. J., O'Callaghan, C. A., Gloyn, A. L., Altshuler, D., Boehnke, M., Teslovich, T. M., McCarthy, M. I., Morris, A. P., Replication, D. I. G., and Meta-analysis, C. (2015) Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. *Nat Genet* **47**, 1415-1425

87. Mahajan, A., Wessel, J., Willems, S. M., Zhao, W., Robertson, N. R., Chu, A. Y., Gan, W., Kitajima, H., Taliun, D., Rayner, N. W., Guo, X., Lu, Y., Li, M., Jensen, R. A., Hu, Y., Huo, S., Lohman, K. K., Zhang, W., Cook, J. P., Prins, B. P., Flannick, J., Grarup, N., Trubetskoy, V. V., Kravic, J., Kim, Y. J., Rybin, D. V., Yaghootkar, H., Muller-Nurasyid, M., Meidtner, K., Li-Gao, R., Varga, T. V., Marten, J., Li, J., Smith, A. V., An, P., Ligthart, S., Gustafsson, S., Malerba, G., Demirkan, A., Tajes, J. F., Steinthorsdottir, V., Wuttke, M., Lecoeur, C., Preuss, M., Bielak, L. F., Graff, M., Highland, H. M., Justice, A. E., Liu, D. J., Marouli, E., Peloso, G. M., Warren, H. R., Exome, B. P. C., Consortium, M., Consortium, G., Afaq, S., Afzal, S., Ahlqvist, E., Almgren, P., Amin, N., Bang, L. B., Bertoni, A. G., Bombieri, C., Bork-Jensen, J., Brandslund, I., Brody, J. A., Burt, N. P., Canouil, M., Chen, Y. I., Cho, Y. S., Christensen, C., Eastwood, S. V., Eckardt, K. U., Fischer, K., Gambaro, G., Giedraitis, V., Grove, M. L., de Haan, H. G., Hackinger, S., Hai, Y., Han, S., Tybjaerg-Hansen, A., Hivert, M. F., Isomaa, B., Jager, S., Jorgensen, M. E., Jorgensen, T., Karajamaki, A., Kim, B. J., Kim, S. S., Koistinen, H. A., Kovacs, P., Kriebel, J., Kronenberg, F., Lall, K., Lange, L. A., Lee, J. J., Lehne, B., Li, H., Lin, K. H., Linneberg, A., Liu, C. T., Liu, J., Loh, M., Magi, R., Mamakou, V., McKean-Cowdin, R., Nadkarni, G., Neville, M., Nielsen, S. F., Ntalla, I., Peyser, P. A., Rathmann, W., Rice, K., Rich, S. S., Rode, L., Rolandsson, O., Schonherr, S., Selvin, E., Small, K. S., Stancakova, A., Surendran, P., Taylor, K. D., Teslovich, T. M., Thorand, B., Thorleifsson, G., Tin, A., Tonjes, A., Varbo, A., Witte, D. R., Wood, A. R., Yajnik, P., Yao, J., Yengo, L., Young, R., Amouyel, P., Boeing, H., Boerwinkle, E., Bottinger, E. P., Chowdhury, R., Collins, F. S., Dedoussis, G., Dehghan, A., Deloukas, P., Ferrario, M. M., Ferrieres, J., Florez, J. C., Frossard, P., Gudnason, V., Harris, T. B., Heckbert, S. R., Howson, J. M. M., Ingelsson, M., Kathiresan, S., Kee, F., Kuusisto, J., Langenberg, C., Launer, L. J., Lindgren, C. M., Mannisto, S., Meitinger, T., Melander, O., Mohlke, K. L., Moitry, M., Morris, A. D., Murray, A. D., de Mutsert, R., Orho-Melander, M., Owen, K. R., Perola, M., Peters, A., Province, M. A., Rasheed, A., Ridker, P. M., Rivadineira, F., Rosendaal, F. R., Rosengren, A. H., Salomaa, V., Sheu, W. H., Sladek, R., Smith, B. H., Strauch, K., Uitterlinden, A. G., Varma, R., Willer, C. J., Bluher, M., Butterworth, A. S., Chambers, J. C., Chasman, D. I., Danesh, J., van Duijn, C., Dupuis, J., Franco, O. H., Franks, P. W., Froguel, P., Grallert, H., Groop, L., Han, B. G., Hansen, T., Hattersley, A. T., Hayward, C., Ingelsson, E., Kardia, S. L. R., Karpe, F., Kooner, J. S., Kottgen, A., Kuulasmaa, K., Laakso, M., Lin, X., Lind, L., Liu, Y., Loos, R. J. F., Marchini, J., Metspalu, A., Mook-Kanamori, D., Nordestgaard, B. G., Palmer, C. N. A., Pankow, J. S., Pedersen, O., Psaty, B. M., Rauramaa, R., Sattar, N., Schulze, M. B., Soranzo, N., Spector, T. D., Stefansson, K., Stumvoll, M., Thorsteinsdottir, U., Tuomi, T., Tuomilehto, J., Wareham, N. J., Wilson, J. G., Zeggini, E., Scott, R. A., Barroso, I., Frayling, T. M., Goodarzi, M. O., Meigs, J. B., Boehnke, M., Saleheen, D., Morris, A. P., Rotter, J. I., and McCarthy, M. I. (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat Genet* **50**, 559-571
88. Guindo-Martinez, M., Amela, R., Bonas-Guarch, S., Puiggros, M., Salvo, C., Miguel-Escalada, I., Carey, C. E., Cole, J. B., Rueger, S., Atkinson, E., Leong, A., Sanchez, F., Ramon-Cortes, C., Ejarque, J., Palmer, D. S., Kurki, M., FinnGen, C., Aragam, K., Florez, J. C., Badia, R. M., Mercader, J. M., and Torrents, D. (2021) The impact of non-additive genetic associations on age-related complex diseases. *Nat Commun* **12**, 2436
89. Hebert, H. L., Shepherd, B., Milburn, K., Veluchamy, A., Meng, W., Carr, F., Donnelly, L. A., Tavendale, R., Leese, G., Colhoun, H. M., Dow, E., Morris, A. D., Doney, A. S., Lang, C. C., Pearson, E. R., Smith, B. H., and Palmer, C. N. A. (2018) Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). *Int J Epidemiol* **47**, 380-381j
90. Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N., Ikegawa, S., Hirata, M., Matsuda, K., Kubo, M., Okada, Y., and Kamatani, Y. (2018) Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat Genet* **50**, 390-400

91. Laakso, M., Kuusisto, J., Stancakova, A., Kuulasmaa, T., Pajukanta, P., Lusi, A. J., Collins, F. S., Mohlke, K. L., and Boehnke, M. (2017) The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. *J Lipid Res* **58**, 481-493
92. Morris, A. P., Voight, B. F., Teslovich, T. M., Ferreira, T., Segre, A. V., Steinthorsdottir, V., Strawbridge, R. J., Khan, H., Grallert, H., Mahajan, A., Prokopenko, I., Kang, H. M., Dina, C., Esko, T., Fraser, R. M., Kanoni, S., Kumar, A., Lagou, V., Langenberg, C., Luan, J., Lindgren, C. M., Muller-Nurasyid, M., Pechlivanis, S., Rayner, N. W., Scott, L. J., Wiltshire, S., Yengo, L., Kinnunen, L., Rossin, E. J., Raychaudhuri, S., Johnson, A. D., Dimas, A. S., Loos, R. J., Vedantam, S., Chen, H., Florez, J. C., Fox, C., Liu, C. T., Rybin, D., Couper, D. J., Kao, W. H., Li, M., Cornelis, M. C., Kraft, P., Sun, Q., van Dam, R. M., Stringham, H. M., Chines, P. S., Fischer, K., Fontanillas, P., Holmen, O. L., Hunt, S. E., Jackson, A. U., Kong, A., Lawrence, R., Meyer, J., Perry, J. R., Platou, C. G., Potter, S., Rehnberg, E., Robertson, N., Sivapalaratnam, S., Stancakova, A., Stirrups, K., Thorleifsson, G., Tikkanen, E., Wood, A. R., Almgren, P., Atalay, M., Benediktsson, R., Bonnycastle, L. L., Burt, N., Carey, J., Charpentier, G., Crenshaw, A. T., Doney, A. S., Dorkhan, M., Edkins, S., Emilsson, V., Eury, E., Forsen, T., Gertow, K., Gigante, B., Grant, G. B., Groves, C. J., Guiducci, C., Herder, C., Hreidarsson, A. B., Hui, J., James, A., Jonsson, A., Rathmann, W., Klopp, N., Kravic, J., Krjutskov, K., Langford, C., Leander, K., Lindholm, E., Lobbens, S., Mannisto, S., Mirza, G., Muhleisen, T. W., Musk, B., Parkin, M., Rallidis, L., Saramies, J., Sennblad, B., Shah, S., Sigurdsson, G., Silveira, A., Steinbach, G., Thorand, B., Trakalo, J., Veglia, F., Wennauer, R., Winckler, W., Zabaneh, D., Campbell, H., van Duijn, C., Uitterlinden, A. G., Hofman, A., Sijbrands, E., Abecasis, G. R., Owen, K. R., Zeggini, E., Trip, M. D., Forouhi, N. G., Syvanen, A. C., Eriksson, J. G., Peltonen, L., Nothen, M. M., Balkau, B., Palmer, C. N., Lyssenko, V., Tuomi, T., Isomaa, B., Hunter, D. J., Qi, L., Wellcome Trust Case Control, C., Meta-Analyses of, G., Insulin-related traits Consortium, I., Genetic Investigation of, A. T. C., Asian Genetic Epidemiology Network-Type 2 Diabetes, C., South Asian Type 2 Diabetes, C., Shuldiner, A. R., Roden, M., Barroso, I., Wilsgaard, T., Beilby, J., Hovingh, K., Price, J. F., Wilson, J. F., Rauramaa, R., Lakka, T. A., Lind, L., Dedoussis, G., Njolstad, I., Pedersen, N. L., Khaw, K. T., Wareham, N. J., Keinänen-Kiukkaanniemi, S. M., Saaristo, T. E., Korpi-Hyovalti, E., Saltevo, J., Laakso, M., Kuusisto, J., Metspalu, A., Collins, F. S., Mohlke, K. L., Bergman, R. N., Tuomilehto, J., Boehm, B. O., Gieger, C., Hveem, K., Cauchi, S., Froguel, P., Baldassarre, D., Tremoli, E., Humphries, S. E., Saleheen, D., Danesh, J., Ingelsson, E., Ripatti, S., Salomaa, V., Erbel, R., Jockel, K. H., Moebus, S., Peters, A., Illig, T., de Faire, U., Hamsten, A., Morris, A. D., Donnelly, P. J., Frayling, T. M., Hattersley, A. T., Boerwinkle, E., Melander, O., Kathiresan, S., Nilsson, P. M., Deloukas, P., Thorsteinsdottir, U., Groop, L. C., Stefansson, K., Hu, F., Pankow, J. S., Dupuis, J., Meigs, J. B., Altshuler, D., Boehnke, M., McCarthy, M. I., Replication, D. I. G., and Meta-analysis, C. (2012) Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet* **44**, 981-990
93. Ng, M. C., Shriner, D., Chen, B. H., Li, J., Chen, W. M., Guo, X., Liu, J., Bielinski, S. J., Yanek, L. R., Nalls, M. A., Comeau, M. E., Rasmussen-Torvik, L. J., Jensen, R. A., Evans, D. S., Sun, Y. V., An, P., Patel, S. R., Lu, Y., Long, J., Armstrong, L. L., Wagenknecht, L., Yang, L., Snively, B. M., Palmer, N. D., Mudgal, P., Langefeld, C. D., Keene, K. L., Freedman, B. I., Mychaleckyj, J. C., Nayak, U., Raffel, L. J., Goodarzi, M. O., Chen, Y. D., Taylor, H. A., Jr., Correa, A., Sims, M., Couper, D., Pankow, J. S., Boerwinkle, E., Adeyemo, A., Doumatey, A., Chen, G., Mathias, R. A., Vaidya, D., Singleton, A. B., Zonderman, A. B., Igo, R. P., Jr., Sedor, J. R., Consortium, F., Kabagambe, E. K., Siscovick, D. S., McKnight, B., Rice, K., Liu, Y., Hsueh, W. C., Zhao, W., Bielak, L. F., Kraja, A., Province, M. A., Bottinger, E. P., Gottesman, O., Cai, Q., Zheng, W., Blot, W. J., Lowe, W. L., Pacheco, J. A., Crawford, D. C., e, M. C., Consortium, D., Grundberg, E., Mu, T. C., Rich, S. S., Hayes, M. G., Shu, X. O., Loos, R. J., Borecki, I. B., Peyser, P. A., Cummings, S. R., Psaty, B. M., Fornage, M., Iyengar, S. K., Evans, M. K., Becker, D. M., Kao, W. H., Wilson, J. G., Rotter, J. I., Sale, M. M., Liu, S., Rotimi, C. N., Bowden, D. W., and



- Consortium, M. E.-a. o. t. D. i. A. A. (2014) Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. *PLoS Genet* **10**, e1004517
94. Replication, D. I. G., Meta-analysis, C., Asian Genetic Epidemiology Network Type 2 Diabetes, C., South Asian Type 2 Diabetes, C., Mexican American Type 2 Diabetes, C., Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples, C., Mahajan, A., Go, M. J., Zhang, W., Below, J. E., Gaulton, K. J., Ferreira, T., Horikoshi, M., Johnson, A. D., Ng, M. C., Prokopenko, I., Saleheen, D., Wang, X., Zeggini, E., Abecasis, G. R., Adair, L. S., Almgren, P., Atalay, M., Aung, T., Baldassarre, D., Balkau, B., Bao, Y., Barnett, A. H., Barroso, I., Basit, A., Been, L. F., Beilby, J., Bell, G. I., Benediktsson, R., Bergman, R. N., Boehm, B. O., Boerwinkle, E., Bonnycastle, L. L., Burt, N., Cai, Q., Campbell, H., Carey, J., Cauchi, S., Caulfield, M., Chan, J. C., Chang, L. C., Chang, T. J., Chang, Y. C., Charpentier, G., Chen, C. H., Chen, H., Chen, Y. T., Chia, K. S., Chidambaram, M., Chines, P. S., Cho, N. H., Cho, Y. M., Chuang, L. M., Collins, F. S., Cornelis, M. C., Couper, D. J., Crenshaw, A. T., van Dam, R. M., Danesh, J., Das, D., de Faire, U., Dedoussis, G., Deloukas, P., Dimas, A. S., Dina, C., Doney, A. S., Donnelly, P. J., Dorkhan, M., van Duijn, C., Dupuis, J., Edkins, S., Elliott, P., Emilsson, V., Erbel, R., Eriksson, J. G., Escobedo, J., Esko, T., Eury, E., Florez, J. C., Fontanillas, P., Forouhi, N. G., Forsen, T., Fox, C., Fraser, R. M., Frayling, T. M., Froguel, P., Frossard, P., Gao, Y., Gertow, K., Gieger, C., Gigante, B., Grallert, H., Grant, G. B., Grrop, L. C., Groves, C. J., Grundberg, E., Guiducci, C., Hamsten, A., Han, B. G., Hara, K., Hassanali, N., Hattersley, A. T., Hayward, C., Hedman, A. K., Herder, C., Hofman, A., Holmen, O. L., Hovingh, K., Hreidarsson, A. B., Hu, C., Hu, F. B., Hui, J., Humphries, S. E., Hunt, S. E., Hunter, D. J., Hveem, K., Hydrie, Z. I., Ikegami, H., Illig, T., Ingelsson, E., Islam, M., Isomaa, B., Jackson, A. U., Jafar, T., James, A., Jia, W., Jockel, K. H., Jonsson, A., Jowett, J. B., Kadowaki, T., Kang, H. M., Kanoni, S., Kao, W. H., Kathiresan, S., Kato, N., Katulanda, P., Keinänen-Kiukaanniemi, K. M., Kelly, A. M., Khan, H., Khaw, K. T., Khor, C. C., Kim, H. L., Kim, S., Kim, Y. J., Kinnunen, L., Klopp, N., Kong, A., Korpi-Hyovalti, E., Kowlessur, S., Kraft, P., Kravic, J., Kristensen, M. M., Krithika, S., Kumar, A., Kumate, J., Kuusisto, J., Kwak, S. H., Laakso, M., Lagou, V., Lakka, T. A., Langenberg, C., Langford, C., Lawrence, R., Leander, K., Lee, J. M., Lee, N. R., Li, M., Li, X., Li, Y., Liang, J., Liju, S., Lim, W. Y., Lind, L., Lindgren, C. M., Lindholm, E., Liu, C. T., Liu, J. J., Lobbens, S., Long, J., Loos, R. J., Lu, W., Luan, J., Lyssenko, V., Ma, R. C., Maeda, S., Magi, R., Mannisto, S., Matthews, D. R., Meigs, J. B., Melander, O., Metspalu, A., Meyer, J., Mirza, G., Mihailov, E., Moebus, S., Mohan, V., Mohlke, K. L., Morris, A. D., Muhleisen, T. W., Muller-Nurasyid, M., Musk, B., Nakamura, J., Nakashima, E., Navarro, P., Ng, P. K., Nica, A. C., Nilsson, P. M., Njolstad, I., Nothen, M. M., Ohnaka, K., Ong, T. H., Owen, K. R., Palmer, C. N., Pankow, J. S., Park, K. S., Parkin, M., Pechlivanis, S., Pedersen, N. L., Peltonen, L., Perry, J. R., Peters, A., Pinidiyapathirage, J. M., Platou, C. G., Potter, S., Price, J. F., Qi, L., Radha, V., Rallidis, L., Rasheed, A., Rathman, W., Rauramaa, R., Raychaudhuri, S., Rayner, N. W., Rees, S. D., Rehnberg, E., Ripatti, S., Robertson, N., Roden, M., Rossin, E. J., Rudan, I., Rybin, D., Saaristo, T. E., Salomaa, V., Saltevo, J., Samuel, M., Sanghera, D. K., Saramies, J., Scott, J., Scott, L. J., Scott, R. A., Segre, A. V., Sehmi, J., Sennblad, B., Shah, N., Shah, S., Shera, A. S., Shu, X. O., Shuldiner, A. R., Sigurdsson, G., Sijbrands, E., Silveira, A., Sim, X., Sivapalaratnam, S., Small, K. S., So, W. Y., Stancakova, A., Stefansson, K., Steinbach, G., Steinthorsdottir, V., Stirrups, K., Strawbridge, R. J., Stringham, H. M., Sun, Q., Suo, C., Syvanen, A. C., Takayanagi, R., Takeuchi, F., Tay, W. T., Teslovich, T. M., Thorand, B., Thorleifsson, G., Thorsteinsdottir, U., Tikkanen, E., Trakalo, J., Tremoli, E., Trip, M. D., Tsai, F. J., Tuomi, T., Tuomilehto, J., Uitterlinden, A. G., Valladares-Salgado, A., Vedantam, S., Veglia, F., Voight, B. F., Wang, C., Wareham, N. J., Wennauer, R., Wickremasinghe, A. R., Wilsgaard, T., Wilson, J. F., Wiltshire, S., Winckler, W., Wong, T. Y., Wood, A. R., Wu, J. Y., Wu, Y., Yamamoto, K., Yamauchi, T., Yang, M., Yengo, L., Yokota, M., Young, R., Zabaneh, D., Zhang, F., Zhang, R., Zheng, W., Zimmet, P. Z., Altshuler, D., Bowden, D. W., Cho, Y. S., Cox, N. J., Cruz, M., Hanis, C. L.,

Kooner, J., Lee, J. Y., Seielstad, M., Teo, Y. Y., Boehnke, M., Parra, E. J., Chambers, J. C., Tai, E. S., McCarthy, M. I., and Morris, A. P. (2014) Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet* **46**, 234-244

95. Scott, R. A., Scott, L. J., Magi, R., Marullo, L., Gaulton, K. J., Kaakinen, M., Pervjakova, N., Pers, T. H., Johnson, A. D., Eicher, J. D., Jackson, A. U., Ferreira, T., Lee, Y., Ma, C., Steinthorsdottir, V., Thorleifsson, G., Qi, L., Van Zuydam, N. R., Mahajan, A., Chen, H., Almgren, P., Voight, B. F., Grallert, H., Muller-Nurasyid, M., Ried, J. S., Rayner, N. W., Robertson, N., Karssen, L. C., van Leeuwen, E. M., Willems, S. M., Fuchsberger, C., Kwan, P., Teslovich, T. M., Chanda, P., Li, M., Lu, Y., Dina, C., Thuillier, D., Yengo, L., Jiang, L., Sparso, T., Kestler, H. A., Chheda, H., Eisele, L., Gustafsson, S., Franberg, M., Strawbridge, R. J., Benediktsson, R., Hreidarsson, A. B., Kong, A., Sigurethsson, G., Kerrison, N. D., Luan, J., Liang, L., Meitinger, T., Roden, M., Thorand, B., Esko, T., Mihailov, E., Fox, C., Liu, C. T., Rybin, D., Isomaa, B., Lyssenko, V., Tuomi, T., Couper, D. J., Pankow, J. S., Grarup, N., Have, C. T., Jorgensen, M. E., Jorgensen, T., Linneberg, A., Cornelis, M. C., van Dam, R. M., Hunter, D. J., Kraft, P., Sun, Q., Edkins, S., Owen, K. R., Perry, J. R. B., Wood, A. R., Zeggini, E., Tajer-Fernandes, J., Abecasis, G. R., Bonnycastle, L. L., Chines, P. S., Stringham, H. M., Koistinen, H. A., Kinnunen, L., Sennblad, B., Muhleisen, T. W., Nothen, M. M., Pechlivanis, S., Baldassarre, D., Gertow, K., Humphries, S. E., Tremoli, E., Klopp, N., Meyer, J., Steinbach, G., Wennauer, R., Eriksson, J. G., Mnnisto, S., Peltonen, L., Tikkanen, E., Charpentier, G., Eury, E., Lobbens, S., Gigante, B., Leander, K., McLeod, O., Bottinger, E. P., Gottesman, O., Ruderfer, D., Bluher, M., Kovacs, P., Tonjes, A., Maruthur, N. M., Scapoli, C., Erbel, R., Jockel, K. H., Moebus, S., de Faire, U., Hamsten, A., Stumvoll, M., Deloukas, P., Donnelly, P. J., Frayling, T. M., Hattersley, A. T., Ripatti, S., Salomaa, V., Pedersen, N. L., Boehm, B. O., Bergman, R. N., Collins, F. S., Mohlke, K. L., Tuomilehto, J., Hansen, T., Pedersen, O., Barroso, I., Lannfelt, L., Ingelsson, E., Lind, L., Lindgren, C. M., Cauchi, S., Froguel, P., Loos, R. J. F., Balkau, B., Boeing, H., Franks, P. W., Barricarte Gurrea, A., Palli, D., van der Schouw, Y. T., Altshuler, D., Groop, L. C., Langenberg, C., Wareham, N. J., Sijbrands, E., van Duijn, C. M., Florez, J. C., Meigs, J. B., Boerwinkle, E., Gieger, C., Strauch, K., Metspalu, A., Morris, A. D., Palmer, C. N. A., Hu, F. B., Thorsteinsdottir, U., Stefansson, K., Dupuis, J., Morris, A. P., Boehnke, M., McCarthy, M. I., Prokopenko, I., Replication, D. I. G., and Meta-analysis, C. (2017) An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes* **66**, 2888-2902
96. Spracklen, C. N., Horikoshi, M., Kim, Y. J., Lin, K., Bragg, F., Moon, S., Suzuki, K., Tam, C. H. T., Tabara, Y., Kwak, S. H., Takeuchi, F., Long, J., Lim, V. J. Y., Chai, J. F., Chen, C. H., Nakatochi, M., Yao, J., Choi, H. S., Iyengar, A. K., Perrin, H. J., Brotman, S. M., van de Bunt, M., Gloyn, A. L., Below, J. E., Boehnke, M., Bowden, D. W., Chambers, J. C., Mahajan, A., McCarthy, M. I., Ng, M. C. Y., Petty, L. E., Zhang, W., Morris, A. P., Adair, L. S., Akiyama, M., Bian, Z., Chan, J. C. N., Chang, L. C., Chee, M. L., Chen, Y. I., Chen, Y. T., Chen, Z., Chuang, L. M., Du, S., Gordon-Larsen, P., Gross, M., Guo, X., Guo, Y., Han, S., Howard, A. G., Huang, W., Hung, Y. J., Hwang, M. Y., Hwu, C. M., Ichihara, S., Isono, M., Jang, H. M., Jiang, G., Jonas, J. B., Kamatani, Y., Katsuya, T., Kawaguchi, T., Khor, C. C., Kohara, K., Lee, M. S., Lee, N. R., Li, L., Liu, J., Luk, A. O., Lv, J., Okada, Y., Pereira, M. A., Sabanayagam, C., Shi, J., Shin, D. M., So, W. Y., Takahashi, A., Tomlinson, B., Tsai, F. J., van Dam, R. M., Xiang, Y. B., Yamamoto, K., Yamauchi, T., Yoon, K., Yu, C., Yuan, J. M., Zhang, L., Zheng, W., Igase, M., Cho, Y. S., Rotter, J. I., Wang, Y. X., Sheu, W. H. H., Yokota, M., Wu, J. Y., Cheng, C. Y., Wong, T. Y., Shu, X. O., Kato, N., Park, K. S., Tai, E. S., Matsuda, F., Koh, W. P., Ma, R. C. W., Maeda, S., Millwood, I. Y., Lee, J., Kadowaki, T., Walters, R. G., Kim, B. J., Mohlke, K. L., and Sim, X. (2020) Identification of type 2 diabetes loci in 433,540 East Asian individuals. *Nature* **582**, 240-245
97. Wessel, J., Majarian, T. D., Highland, H. M., Raghavan, S., Szeto, M. D., Hasbani, N. R., de Vries, P. S., Brody, J. A., Sarnowski, C., DiCorpo, D., Yin, X., Hidalgo, B., Guo, X., Perry, J., O'Connell, J. R., Lent, S., Montasser, M. E., Cade, B. E., Jain, D., Wang, H., Wu, P., Bonàs-

- Guarch, S., D'Oliveira Albanus, R., Leong, A., Miguel-Escalada, I., Varshney, A., NHLBI Trans-Omics for Precision Medicine Consortium, T. A., DIAMANTE, Kinney, G. L., Yanek, L. R., Lange, L., Almeida, M., Peralta, J. M., Aslibekyan, S., Baldridge, A. S., Bertoni, A. G., Bielak, L. F., Bowden, D. W., Chen, C.-S., Chen, Y.-D. I., Choi, S. H., Choi, W. J., Darbar, D., Floyd, J. S., Freedman, B. I., Goodarzi, M. O., Irvin, R., Kalyani, R. R., Kelly, T., Lee, S., Liu, C.-T., Loesch, D., Manson, J. E., Nassir, R., Palmer, N. D., Pankow, J. S., Rasmussen-Torvik, L. J., Reiner, A. P., Selvin, E., Shadyab, A. H., Smith, J. A., Weeks, D. E., Weng, L.-C., Xu, H., Yao, J., Yoneda, Z., Zhao, W., Ferrer, J., Mahajan, A., McCarthy, M. I., Parker, S., Alonso, A., Arnett, D. K., Blangero, J., Boerwinkle, E., Cho, M. H., Correa, A., Cupples, L. A., Curran, J. E., Duggirala, R., Ellinor, P. T., He, J., Heckbert, S. R., Kardia, S. L., Kim, R. W., Kooperberg, C., Liu, S., Lubitz, S. A., Mathias, R. A., McGarvey, S., Mitchell, B. D., Morrison, A. C., Peyser, P. A., Psaty, B. M., Redline, S., Roden, D., Shoemaker, M. B., Smith, N. L., Taylor, K. D., Vasan, R. S., Viaud-Martinez, K. A., Florez, J. C., Wilson, J. G., Sladek, R., Dupuis, J., Rich, S. S., Rotter, J. I., Meigs, J. B., and Manning, A. K. (2020) Rare Non-coding Variation Identified by Large Scale Whole Genome Sequencing Reveals Unexplained Heritability of Type 2 Diabetes. *medRxiv*, 2020.2011.2013.20221812
98. Zhao, W., Rasheed, A., Tikkanen, E., Lee, J. J., Butterworth, A. S., Howson, J. M. M., Assimes, T. L., Chowdhury, R., Orho-Melander, M., Damrauer, S., Small, A., Asma, S., Imamura, M., Yamauch, T., Chambers, J. C., Chen, P., Sapkota, B. R., Shah, N., Jabeen, S., Surendran, P., Lu, Y., Zhang, W., Imran, A., Abbas, S., Majeed, F., Trindade, K., Qamar, N., Mallick, N. H., Yaqoob, Z., Saghir, T., Rizvi, S. N. H., Memon, A., Rasheed, S. Z., Memon, F. U., Mehmood, K., Ahmed, N., Qureshi, I. H., Tanveer Us, S., Iqbal, W., Malik, U., Mehra, N., Kuo, J. Z., Sheu, W. H., Guo, X., Hsiung, C. A., Juang, J. J., Taylor, K. D., Hung, Y. J., Lee, W. J., Quertermous, T., Lee, I. T., Hsu, C. C., Bottinger, E. P., Ralhan, S., Teo, Y. Y., Wang, T. D., Alam, D. S., Di Angelantonio, E., Epstein, S., Nielsen, S. F., Nordestgaard, B. G., Tybjaerg-Hansen, A., Young, R., Consortium, C. H. D. E., Benn, M., Frikke-Schmidt, R., Kamstrup, P. R., Consortium, E.-C., Consortium, E. P.-I., Michigan, B., Jukema, J. W., Sattar, N., Smit, R., Chung, R. H., Liang, K. W., Anand, S., Sanghera, D. K., Ripatti, S., Loos, R. J. F., Kooner, J. S., Tai, E. S., Rotter, J. I., Chen, Y. I., Frossard, P., Maeda, S., Kadowaki, T., Reilly, M., Pare, G., Melander, O., Salomaa, V., Rader, D. J., Danesh, J., Voight, B. F., and Saleheen, D. (2017) Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. *Nat Genet* **49**, 1450-1457